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The debate over state-funded provision of PrEP for HIV prevention in the UK has intensified in recent 
years due to the establishment of the PrEP Impact Trial and a legal challenge to the NHS’ decision not 
to commission the drug. This thesis explores the ethical and economic issues associated with the 
provision of PrEP. 
I begin with an appraisal of an existing economic analysis of PrEP, highlighting its shortcomings 
and detailing the sensitivity analyses required for a more useful future analysis. 
Three key ethical issues are then explored: adherence, risk compensation, and effective 
targeting. They are considered in the context of principlism and the importance of autonomy relative 
to other values. A broadly utilitarian approach is also taken in balancing benefits and harms, accounting 
for the impact these issues might have on the wider community and population. 
Policy implications form the conclusion, providing a suggested way forward. First and foremost, 
I demonstrate a clear need for further research and economic analysis, noting the arguably hurried 
nature of PrEP provision. I also argue for daily PrEP to become the default method of dosing, with event-
based PrEP kept as a reserve to be sparingly used at the discretion of doctors when clearly appropriate. 
With PrEP as the appropriate default now, a defence of long-acting injectable PrEP as the default is 
provided in anticipation of its introduction. Finally, I call for additional efforts to minimise the 
prevalence of risk compensation and prevention optimism; potential methods are highlighted, such as 
counselling and SMS reminders.  
The overarching conclusion of this thesis is that the introduction of PrEP has been rushed, and 
there are several unanswered questions. In order to provide PrEP in the most useful and ethical way 
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Pre-exposure prophylaxis (PrEP) for those at high risk of human immunodeficiency virus 1 (HIV-
1)1 infection through sexual contact is a means of drastically reducing that risk and may contribute 
to a decrease in infection rates. However, the suggestion of introducing free access to the drug 
for high-risk populations in the United Kingdom (UK) through the National Health Service (NHS) 
has proved contentious. The drug is highly efficacious (Molina et al., 2015; Grant et al., 2010; 
McCormack et al., 2016) though we know less of its effectiveness. Even if PrEP were to be 
effective in reducing the number of new HIV infections, state provision raises interesting ethical 
questions: the relationship between individual autonomy and the protection of public health; 
justice in resource allocation; and nonmaleficence. Whether to make PrEP available through the 
NHS is more than a question of cost-effectiveness; myriad social and ethical issues must be 
considered.  
 
I explore these issues and consider if and how the NHS can ethically commission PrEP for men 
who have sex with men (MSM) at high risk of HIV infection through sexual contact. I am concerned 
only with this population group. Other groups are at high risk of infection, such as healthcare 
professionals and intravenous drug users, though provision of PrEP for these groups would 
involve different ethical issues. Furthermore, past and current PrEP trials and schemes of 
provision, in addition to the current debate, have been and are concerned almost exclusively with 
the spread of HIV through sexual contact among MSM. 
 
Before outlining the relevant ethical issues, I first provide a history of HIV and prevention 
methods. This background is important to understanding the implications of any changes to HIV 
prevention practices. 
 




HIV and prevention history 
 
HIV can be traced back to 1920s Kinshasa, the capital of what is now the Democratic Republic of 
Congo (Faria et al., 2014). The current epidemic, however, is recognized as having started in the 
1980s in the United States of America (USA). The outbreak was first observed among homosexual 
men, resulting in the disease being referred to in ways involving the word ‘gay’ (Brennan and 
Durack, 1981), though cases were soon documented among other populations, such as 
haemophiliacs (Centers for Disease Control and Prevention, 1982). 
 
Whilst few populations were affected initially, we now know HIV is a risk to all. No one is immune 
to the virus, but those acknowledged to be at the highest risk of infection through sexual contact 
are MSM. In 2017, MSM accounted for 53% of new HIV infections in the UK (Public Health 
England, 2018). Considering only 2% of the UK population identify2 as lesbian, gay, or bisexual 
(Office for National Statistics, 2019) this is a significant increased risk. The balance of new 
infections among heterosexuals compared to MSM is shifting in the UK – both are on downward 
trajectories, though MSM are on a steeper one – but MSM still account for the majority of new 
infections (Public Health England, 2018). 
 
Since the 1980s outbreak, condoms have been promoted as the recommended preventative 
measure against sexual transmission of the virus. This is because condom efficacy is c. 98% 
(National Health Service, 2017b), and condoms protect against not only HIV but also most other 
sexually transmitted infections (STIs),3 in addition to acting as a contraceptive where relevant. 
 
2 The population will be larger as some may choose to identify as heterosexual but are still MSM. 




Furthermore, the c. 2% of times when condoms fail (i.e. break) it is possible to check, better 
enabling one to minimise the risk of infection following potential or likely exposure to the virus. 
However, despite continued promotion of condom use, the number of new HIV infections in the 
UK each year remains high (Public Health England, 2018). 
 
Renewed hope in the battle against HIV came in 2004 with the approval of the drug Truvada in 
the USA (United States Food and Drug Administration, 2004). Initially developed as antiretroviral 
treatment (ART) for HIV-positive (HIV+) individuals, Truvada contains two antiretroviral 
medications (emtricitabine and tenofovir disoproxil fumarate, sometimes written 
emtricitabine/tenofovir) in a fixed-dose combination (Gilead Sciences, 2018). The drug acts to 
reduce the activity of the enzyme reverse transcriptase which HIV-infected cells use to make new 
viruses. In doing so it stops HIV-infected cells from making new viruses, or at least slows the 
process (Hosein, 2016). 
 
Truvada has since been used as post-exposure prophylaxis following sexual exposure to HIV (PEP 
or PEPSE). PEP is the emergency use of antiretrovirals shortly after confirmed or suspected 
exposure to HIV to prevent the virus taking hold. It is a 28-day course of drugs to be started as 
soon after exposure as possible – ideally within hours. It is possible to start PEP up to 72 hours 
after exposure, though within 24 hours is considered best (Cresswell et al., 2016). 
 
It is difficult to assess how effective PrEP is in preventing HIV infection, but it is even more difficult 
with PEP. It varies significantly depending on how soon after exposure a user commences 




Organization (WHO) states that if started soon after exposure and with full adherence, PEP 
reduces the risk of HIV infection by over 80% (World Health Organisation, 2014).  
 
PEP is available through the NHS across the UK as an emergency treatment intended for instances 
such as a split condom, or when a condom was not used for some reason by individuals who 
would ordinarily have used one4. PEP is less efficacious than both condoms and PrEP (combined 
or individually) in preventing an infection and should not be considered a key part of one’s long-
term sexual health practices (Cresswell et al., 2016). 
 
What is PrEP? 
 
Truvada is also now used as PrEP. This use has proved controversial, despite the WHO 
recommending Truvada for HIV prevention among certain high-risk population groups (World 
Health Organisation, 2016). 
 
Pre-exposure prophylaxis refers to the use of drugs to prevent an infection in those who have not 
been exposed to it. Whilst this literal definition is general, the term “PrEP” is often used when 
referring specifically to the use of antiretroviral drugs as a preventative measure against HIV. 
Truvada is the brand most commonly used for PrEP – indeed “PrEP” and “Truvada” are often used 
interchangeably – though generics are now available. 
 
 
4 These are examples of emergencies that would justify PEP. They are not the only examples. PEP may also 




I focus on PrEP as prevention against HIV-1 because this strain of the virus is most prevalent, 
accounting for the vast majority of HIV infections globally (Nyamweya et al., 2013). HIV-2 is less 
easily transmitted and is rarely found outside of West Africa, so is less relevant to a discussion of 
HIV prevention in the UK. Any use of the term “PrEP” from now refers to this specific meaning. 
 
Unlike a vaccination, PrEP requires continued use. Recommended practice is a single daily dose, 
taken orally. Event-based use is sometimes practiced (see Chapter IV), but a single daily dose is 
preferable due to greater ease of adherence with a routine medication. Research into a monthly 
or quarterly injectable form of the drug is showing promising results (Evans, 2014; Kaltwasser, 
2018). It is possible that PrEP users will switch to long-acting injectable PrEP (LAI-PrEP) in time, 
though it is currently still being trialled (see Chapter IV). 
 
It is important those starting PrEP test negative for HIV. This is to minimize any risk that the virus 
will develop resistance to the medications found in Truvada, as HIV+ individuals are treated with 
different drug combinations and dosing. For this reason, trials require potential participants to 
undergo HIV testing before enrolling. 
 
PrEP efficacy is high. Efficacy refers to the maximum capacity of a drug to fulfil its purpose(s), in 
contrast to effectiveness which is the capacity of the drug to fulfil its purpose(s) in real life 
conditions; effectiveness accounts for other factors, such as adherence. Studies place PrEP’s 
efficacy as high as a 99% HIV risk reduction (Anderson et al., 2012). The risk reduction, however, 
diminishes when a user fails to adhere to daily dosing. Therefore, risk reduction as high as 99% 
rests on strict adherence. High efficacy does not necessarily entail high effectiveness, therefore 




occasionally missed doses of PrEP; indeed, PrEP is presented as an additional precaution and not 
as a condom substitute (PrEP Impact Trial, 2017a). 
 
Whilst we do know that PrEP is efficacious, things are less certain when it comes to effectiveness. 
Whilst acknowledging potential wider problems with the provision of PrEP, major past trials were 
efficacy trials rather than effectiveness (Molina et al., 2015; Grant et al., 2010). Literature 
concerning the ethical and social implications when effectiveness is considered – at both the 
individual- and population-level – is mostly limited to the media and campaign materials. This 
material, though useful to study, is political rather than academic in nature. It is characterized by 
broad statements which potentially hold some truth, though are frequently unsupported. One 
exception is the National Institute for Health and Care Excellence’s (NICE) 2016 evidence 
summary. Through a review of four randomized trials of Truvada the summary purports to 
explore not only PrEP’s efficacy, but also ‘issues relating to uptake, adherence, sexual behaviour, 
drug resistance, safety, prioritization for prophylaxis and cost effectiveness[…]especially at a 
population level’ (National Institute for Health and Care Excellence, 2016). However, the 
summary fails to fully acknowledge the potential impact of these other issues on the number 
needed to treat (NNT)5 and, by extension, the cost-effectiveness. The reason for this is that the 
trials it reviewed are those which focus on efficacy. Whilst efficacy is important, decisions 




5 The number needed to treat is a measure used to illustrate the effectiveness, and by extension cost-
effectiveness, of a healthcare intervention. In the case of PrEP, it refers to the number of individuals who 




The availability of PrEP 
 
Whilst PrEP trials/programmes can vary, they tend to maintain similar eligibility criteria. Usually, 
potential users must be aged 16 or over, test negative for HIV, and be considered within one of 
the predetermined high-risk groups following a clinical risk assessment. Groups classed as high-
risk include MSM who report having had condomless sex in the previous 90 days, and HIV-
negative (HIV-) partners in serodiscordant couples6 whose partners are not known to be virally 
suppressed. There is also discretion in clinical assessment to permit access to the drug for those 
who do not fit the eligibility criteria but who are considered to be similarly high-risk. A more 
detailed explanation of PrEP eligibility is included in Chapter VI. 
 
PrEP is available through the healthcare system in only a small number of countries7, though this 
number is growing. The drug is arguably most easily accessible in Norway. In October 2016, the 
Norwegian National Health Service announced it would provide PrEP to at-risk citizens free of 
charge (Weller, 2016). PrEP was already available for free in France at this time, but under a 
system of emergency recommendation of temporary use (RTU) (Collins, 2015). Truvada is also 
available in the USA, though access varies depending on an individual’s insurance coverage. 
 
Within the UK, which is the focus of this thesis, Scotland was the first and remains the only country 
to provide PrEP outside of a trial. The drug was made available on the NHS in Scotland in July 2017 
 
6 Serodiscordant couples are those in which one partner is known to be infected with HIV and the other is 
not. 
7 That does not mean to say that PrEP is not being used in other countries as both Truvada and generics 
can be easily purchased online, in addition to alternative means of obtaining the drug such as clinic hopping 




(National Health Service Lothian, 2018). Access to PrEP in Scotland is based on the common PrEP 
criteria earlier mentioned. 
 
Wales also made PrEP available in July 2017, though through the PrEPared trial (National Health 
Executive, 2018). Whilst availability in Wales is as part of a trial, there is no cap on the number of 
participants. Therefore, all eligible individuals can access PrEP for the 3-year trial period. Truvada 
was used initially, though the switch to generics was made in summer 2018 (Public Health Wales, 
2018). 
Similarly to Wales, Northern Ireland is trailing PrEP provision with no cap on the number of 
participants (I Want PrEP Now a). It will run for two years, providing access to the drug for all who 
are eligible following similar criteria to those described earlier. Whilst all genitourinary medicine 
(GUM) clinics will offer initial consultation and assessment appointments, those eligible will only 
be able to access PrEP following a referral to a centralised service in Belfast8. 
 
In England, things have been more complicated. Campaigners have long sought freely available 
PrEP. There have been several campaigns, including websites established to inform about PrEP 
and provide purchasing guidance for those willing to pay for the drug themselves (Prepster; I 
Want PrEP Now a). More recently, campaigners protested at the London premiere of ‘Bohemian 
Rhapsody’, the Freddie Mercury biopic, suggesting that PrEP could have prevented Mercury’s 
death (Welsh, 2018). Nonetheless, the NHS in England has not made PrEP freely available, and 
access had been limited to those willing to purchase the drug themselves until a recently 
commenced trial. 
 






The PrEP Impact Trial (PIT) was established by NHS England to inform its decision as to whether 
to commission PrEP (PrEP Impact Trial, 2017b). It is far larger than the trials in Wales and Northern 
Ireland, with the initial budget allowing for 10,000 participants (later increased to 13,000, then 
doubled to 26,000) for a 3-year period and recruitment commenced in October 2017. The PIT 
also hopes to answer more questions about the impact PrEP might have in practice: 
 
 ‘1. How many people attending sexual health clinics need PrEP? 
 2. How many of these start PrEP? 
 3. How long do they need PrEP for?’ (PrEP Impact Trial, 2017b) 
 
The PIT was established as a result of a 2016 legal challenge against the NHS in England 
concerning PrEP provision (R (National AIDS Trust) v NHS Commissioning Board (NHS England) 
2016). The challenge sought to confirm where responsibility for the cost of PrEP would fall if it 
were to be available. NHS England claimed that as PrEP is not treatment it does not fall under its 
remit, and that preventive strategies are the responsibility of local authorities. The High Court 
dismissed this argument and ruled that the NHS can provide PrEP. It is important to note, 
however, that this ruling stated only that the NHS can provide PrEP, not that it must; it remains 
the decision of NHS England as to whether it is deemed a justified expense. 
 
Most recently, Ireland’s Ministers for Health announced a commitment to implementing a PrEP 




the country’s Health Information and Quality Authority. With this being such a recent 




Debate over PrEP provision for those at high risk of HIV transmission through sexual contact has 
been heated. Both sides use loaded and emotive language to attack the other. PrEP supporters 
argue not providing the drug is harming potential users, failing to remove the risk of HIV when an 
“easy” option is available (Kruger, 2015). The opposition suggest spending tax revenue on a 
“promiscuity pill” is unethical when funds could be directed to medical care they deem more 
deserving (Borland et al., 2016). 
 
These simplified arguments exist to populate headlines and garner support by appealing to 
intuitive values. However, they derive from serious concerns. I engage with several of these 
serious concerns through evaluation of the developed concerns they were founded upon. 
 
Through a review of the literature, both academic and activist, I have identified several key ethical 
issues surrounding PrEP provision. Each is dealt with individually to assist in a final assessment of 
the ethical permissibility of state-provided PrEP for MSM in the UK. 
 
Before engaging with these ethical issues, Chapter II introduces the economics of PrEP provision 
by questioning whether the state ought to provide the drug when infection rates for HIV are low 




commissioning, so discussion of PrEP provision must speak to the financial impact. This is 
poignant in the case of PrEP as its provision is objected to on the grounds that the money would 
be better spent elsewhere. Existing cost-effectiveness analyses generally conclude that PrEP is 
cost-effective, however there is reason to question their results. I analyse the most relevant of 
these studies and demonstrate its shortcomings. This illustrates the extent and nature of 
sensitivity analyses necessary, demonstrating that financial arguments concerning PrEP provision 
are not as straightforward as is often suggested. Many associated costs I consider relate to later 
chapters of this thesis, so Chapter II further justifies the importance of the ethical issues I explore. 
 
I then outline relevant ethical theory in Chapter III. This focuses primarily on principlism and the 
interplay between autonomy and the other three principles of nonmaleficence, beneficence, and 
justice. It also draws on ideas of bodily integrity and proportionality as they relate to suggested 
interventions. When discussing bodily integrity, this chapter also introduces the coercion versus 
withholding distinction which I develop, highlighting its utility in debates such as PrEP provision. 
I also address the question of sexual liberation and the role I see it playing in this debate. 
Theoretical stances outlined in this chapter are drawn upon throughout this thesis, making 
Chapter III a useful point of reference. 
 
Chapter IV concerns nonadherence. PrEP effectiveness hinges on the user keeping to the 
prescribed daily dose. If a user may struggle with adherence, it may be unethical to provide the 
drug as it may put that user at risk of HIV infection. The risks of nonadherence are stressed to 
users prior to commencement9, but it may be that we cannot expect them to be sufficiently 
recognized. Users may also suffer nonadherence due to forgetfulness or lack of routine. To assess 
 




the likelihood of widespread nonadherence I first look to PrEP trials/studies which have 
considered the risk. I also examine adherence to both PEP and the birth control pill (BCP) to draw 
parallels with PrEP. Finally, I look to the potential future of PrEP administration and consider what 
LAI-PrEP might mean for adherence. 
 
Arguably the most problematic issue with PrEP provision is risk compensation, which is the 
subject of Chapter V. It is with this issue that one looks beyond the primary purpose of PrEP (i.e. 
HIV prevention) and considers the negative impact provision may have more broadly on the 
individual user, the NHS, and the wider population. Those opposed to PrEP provision argue that 
the drug enables, perhaps even encourages, riskier sexual behaviour (such as a decrease in 
condom use). Users may be at low risk of HIV infection when on PrEP, but they are not protected 
against other STIs unless additional precautions are taken. Therefore, if risk compensation does 
arise, PrEP results in an increased risk of STIs for those users. This is ethically problematic not only 
because that individual is at an increased risk of STIs, but because the wider population is affected 
by an increased spread of STIs. I assess PrEP studies in which risk compensation was measured, 
in particular the PROUD and iPrEx (follow up) studies which both explicitly state they assess the 
effect (McCormack et al., 2016; Grant et al., 2014). I also consider the potential for the seldom 
acknowledged issue of community risk compensation. This is when those not on PrEP engage in 
riskier sexual practices as they believe enough individuals are taking PrEP to reduce the risk of 
transmission throughout the community. I then discuss whether it is ethical to put an individual 
at greater risk of several infections just to reduce their risk of one, discussing the balance between 
personal autonomy and both beneficence and nonmaleficence. 
 
The final issue, which is examined in Chapter VI, is effective targeting. If one were to deem PrEP 




problems associated with PrEP (namely nonadherence and risk compensation) manifesting in 
populations outside of those already at the highest risk of HIV infection, it would be important to 
prevent these other populations accessing the drug. I evaluate the eligibility criteria of the PIT in 
terms of ease of access for those outside the target population. This includes consideration of the 
appropriateness of denying access to those who want PrEP, and whether population-level access 
concerns can justify a blanket denial of PrEP access. 
 
Chapter VII concludes by revisiting economic considerations, informed by ethical discussions. I 
demonstrate that the NNT for PrEP is, in practice, likely to be higher than anticipated by the trials 
reviewed by NICE (National Institute for Health and Care Excellence, 2016). I also argue that the 
NNT is somewhat irrelevant when it comes to PrEP, because clinical risk assessments for eligibility 
are based on the self-reporting of potential users; not only those for whom PrEP would be 
intended would access the drug, thus increasing the cost. This brings the cost-effectiveness of 
PrEP – a key NHS commissioning criterion – into doubt. Further, through highlighting the potential 
relative harm to both the individual and the population caused by widely available PrEP (i.e. the 
availability of PrEP beyond the target population), I argue that the question of state-provision of 
PrEP does not hinge on cost-effectiveness. This clearly marks the importance of considerations 
























































Drug commissioning decisions require consideration of financial costs and benefits; resource 
allocation is informed by health economic evaluations (Husereau et al., 2013). This is 
transparently the case in state-funded systems, such as the UK, though still happens under other 
systems. To justify spending public funds on a new drug, it is generally held that it must be cost-
effective; i.e. ‘if it gives a greater health gain than could be achieved by using the resources in 
other ways’ (National Institute for Health and Care Excellence, 2008). That does not mean to say 
that everything that is cost-effective is appropriate, as other considerations – such as ethical 
implications – must be balanced against cost-effectiveness (National Institute for Health and Care 
Excellence, 2008). Into such considerations also comes the question of opportunity costs in an 
increasingly financially stretched healthcare system; funding PrEP necessarily prevents some 
other service being funded. 
 
The often pivotal role of cost-effectiveness in commissioning necessitates that these studies are 
conducted to the highest possible standard, accounting for associated costs10 and, where 
possible, anticipating the socio-behavioural impact of a drug and how this may affect cost. 
However, the importance of cost-effectiveness does not mean that something can only be 
appropriate if cost-effective. Where cost-effectiveness analysis is considered to have 
misrepresented the health gain in terms of quality of life, or where substantial benefits result 
from the intervention which are not captured in the measurement of health gain, a cost-
ineffective intervention may be considered an appropriate use of NHS resources (National 
Institute for Health and Care Excellence, 2008). 
 
 
10 By associated costs I mean those beyond the cost of the drug itself and the cost of alternative treatments 
in the absence of it. In the case of PrEP, for instance, this means looking beyond the cost of PrEP and the 
cost of HIV treatment should someone become infected. Associated costs do not include indirect costs, 




There are multiple studies of the cost-effectiveness of PrEP, with at least two focusing on UK 
provision (Cambiano et al., 2018; Ong et al., 2017). PrEP is commonly deemed cost-effective, with 
some studies suggesting savings as high as £964m (Cambiano et al., 2018). However, I contend 
there are flaws in the modelling of these studies, and thus reasons to doubt their conclusions. 
This thesis demonstrates that several of the assumptions these studies are based on are 
unjustified and unlikely to be the reality – such as assuming there is no change in sexual 
behaviour, or that full adherence among PrEP users is to be expected. I demonstrate that in failing 
to fully outline and justify their assumptions, these studies have fallen short of the CHEERS 
statement (Husereau et al., 2013). 
 
In highlighting the flaws in existing analyses, I argue there is still a need for a thorough and 
accurate analysis of PrEP’s cost-effectiveness. A discussion of the importance of cost-
effectiveness in PrEP decision-making can only take place following suitable analysis, meaning 
analysis which accounts for the many nuances and additional costs. Whilst such analysis is not 
the purpose of this thesis, I highlight the issues and associated costs I believe were not addressed 
by Cambiano and colleagues, but which ought to be. This contributes to the foundation of a future 
cost-effectiveness study. 
 
The overall purpose of this chapter is to highlight the problematic ethico-economic 
considerations driving commissioning decisions surrounding PrEP. These issues are revisited from 








Whilst there have been several analyses of the cost-effectiveness of PrEP, I limit my analysis to 
the Cambiano study (Cambiano et al., 2018). This study is most relevant to UK PrEP decisions as 
it looks specifically at the UK context and is one of the most recent studies. It is also the Cambiano 
study which has been referenced by the NHS when claiming PrEP could save the Service £1bn11 
(National Health Service, 2017a). 
 
The Cambiano study sought to evaluate the economic implications of PrEP provision, concluding 
that provision of the drug would be cost-saving. It notes the effectiveness of daily PrEP, although 
the study assesses the cost-effectiveness of event-based PrEP rather than daily in its base case12. 
This is a particularly unexpected aspect of the study given it claims to assess cost-effectiveness 
based on the PROUD trial (McCormack et al., 2016) which investigated daily PrEP. Event-based 
PrEP use is likely to be less effective than daily use (see Chapter IV), which immediately puts a 
question mark over this study’s findings when PrEP’s effectiveness is asserted. 
 
Cambiano and colleagues demonstrate that not only is PrEP cost-effective, but cost-saving over 
an 80-year time horizon. There were, however, several issues with the base case which were not 
addressed, or at least inadequately addressed, by sensitivity analyses13. The base case made the 
 
11 This NHS article does note that the assumptions the study is based on may turn out to be false, but merely 
as a concluding remark. The figure of £1bn was rounded from the actual figure of £964m. 
12 Daily PrEP is considered in sensitivity analysis. 
13 Sensitivity analysis is a means of testing the uncertainty of economic analysis by repeating the analysis 
after changing an assumption. For instance, two analyses may be run assuming 100% and 75% adherence 




following problematic assumptions: full adherence, quarterly HIV tests by users, and a mean of 
4.5 years spent on PrEP. 
 
Full adherence is very unlikely (see Chapter IV). Studies demonstrated this prior to the Cambiano 
study (Grant et al., 2010, Molina et al., 2015). Nonadherence arises regardless of dosing option, 
but more so with event-based usage (as was considered in this study) as there is no habit 
established. However, an assumption of full adherence in the base case is not too problematic as 
sensitivity analysis was performed assuming 63% effectiveness as a result of lesser adherence. 
This still produced a cost-saving. Therefore, it is possible nonadherence would not significantly 
affect the cost-effectiveness of PrEP. That is to say that nonadherence alone may not render PrEP 
cost-ineffective but, combined with other cost factors, it may contribute to such a conclusion. 
 
It is, however, important to note cost-effectiveness alone does not justify PrEP. Ethical issues 
associated with nonadherence which are explored later in this thesis (see Chapter IV) are also 
important, so we cannot discard worries over adherence based on it not affecting cost-
effectiveness. 
 
Quarterly HIV tests are potentially enforceable if users are only provided with three months’ 
worth of PrEP at a time. This would ensure users would have to return to obtain more PrEP, and 
a condition of receipt could be sexual health screening. However, this is problematic for those in 
rural areas who are unable to attend a GUM clinic regularly. This is a potential equality of access 
issue. Sensitivity analysis partially accounted for the lack of consistent quarterly HIV tests by 
doubling instances of STIs; less frequent testing enables STIs (and indeed HIV) to spread more 




for STI instances in PrEP users. Given risk compensation (see Chapter V), widespread PrEP may 
result in an increase in STIs not only within the community of PrEP users, but the wider MSM 
community, and potentially even beyond that. Therefore, we may see a greater increase in STIs 
than accounted for, meaning the saving suggested could be unrealistic. Further, there is potential 
for PrEP to be dispensed by pharmacies in time. This would remove any ability to enforce 
quarterly testing, potentially worsening the spread of STIs and, in a worst-case scenario, HIV. An 
infected individual could spread an STI to many in three months, so without quarterly testing STI 
rates may increase more so. 
 
The average PrEP user being on the drug for only 4.5 years is particularly confusing due to its lack 
of justification and accompanying sensitivity analysis. Assuming users will take PrEP for an average 
of 4.5 years and costing PrEP provision on this assumption is problematic for this study’s external 
validity. Given how recently PrEP has been introduced there are not yet studies indicating how 
long an individual might spend on the drug, but 4.5 years seems too few. A more detailed 
exploration of the likely length of time an individual would spend on PrEP is provided shortly when 
I look at the PIT. For now, it is fair to say this study ought to have conducted sensitivity analyses 
for users remaining on PrEP for longer periods of time. The failure to do so undermines the claim 
that PrEP is cost-effective, as it only holds true if users stop taking the drug after an average of 
4.5 years. 
 
I argue that the above makes the study unconvincing in its conclusion that PrEP is cost-effective. 
There are factors that will influence the cost-effectiveness of PrEP which Cambiano and 
colleagues either did not consider, or did not consider in sufficient depth, and thus they have 
demonstrated the cost-effectiveness of a PrEP programme that would not be replicable in 




I will now look at the PIT and the considerations it is making with regards to economics. Whilst 
the explicit purpose of the PIT is not to ascertain the cost-effectiveness of PrEP, many of the 
questions it does hope to answer have cost implications. 
 
The PrEP Impact Trial 
 
The PIT hopes to answer a range of questions regarding, as the name suggests, the impact PrEP 
would have if available on a large scale in England. These range from questions of uptake to risk 
compensation, and many have potential financial implications. 
 
One stated aim is to establish how long PrEP users will stay on the drug (PrEP Impact Trial, 2017c). 
It is hoped that in ascertaining the average length of time spent on PrEP, the drug cost per user 
will become clear. This is important information for commissioning decisions, as highlighted in 
my earlier discussion of existing cost-effectiveness analyses. However, such information is an 
impossible outcome of this trial. The PIT is only a 3-year trial, so in hoping to ascertain average 
time spent on PrEP in this period suggests users will not want or need the drug for more than 
three years. This seems unlikely. 
 
It is reasonable to assume a significant number of PrEP users would continue to take the drug for 
more than three years. Aside from experiencing negative side effects, the only likely reason for 
an individual to stop using PrEP is a significant reduction in perceived personal risk of HIV 
infection. Such a reduction in personal risk may result from a user: entering a closed, 
monogamous sexual relationship with a partner who is either HIV- or HIV+ but virally suppressed; 




last two are not impossible, they do not seem likely; beginning to use condoms consistently after 
not doing so for an extended period of time would likely require significant determination as it 
will not be a habit such an individual will have, and for someone with a history of risky sexual 
activity to suddenly stop having sex altogether can feasibly be deemed rare. 
 
The most likely reason for a user to stop PrEP, then, is entering a closed, monogamous sexual 
relationship with a partner who is either HIV- or HIV+ but virally suppressed. In such a relationship, 
the risk of infection is extremely low. Indeed, infection would only occur in the case of infidelity 
or the HIV+ partner failing to fully adhere to highly active antiretroviral treatment (HAART). For 
most PrEP users to find themselves in a closed, monogamous sexual relationship with a low risk 
partner within three years is a claim which needs supporting. One study explored sexual risk 
behaviours of MSM in serodiscordant relationships and found many have sex with individuals 
other than their primary partner (Brooks et al., 2012). Such individuals would have a continuing 
need for PrEP and may be long-term users. It is feasible, then, that most PrEP users will continue 
to use the drug for far longer than three years. This is because the MSM community is known to 
be less concerned with having closed, monogamous relationships than the heterosexual 





As already mentioned, one issue neglected in cost-effectiveness analyses is associated costs 
which may arise where PrEP is made available. It is not a case of weighing up the cost of PrEP 




to consider, ranging from STI treatments to the clinical time required to counsel a prospective 
PrEP user. Only in accounting for these associated costs can an accurate cost-effectiveness 
analysis be completed. 
 
The first to consider is STI treatment. The extent to which STI infections would increase in MSM 
as a result of increased access to PrEP is hard to determine, as it will be contingent on the extent 
of risk compensation taking place. Cambiano and colleagues assumed no change in sexual 
behaviour among PrEP users (Cambiano et al., 2018) and thus their sensitivity analysis with 
greater instances of STIs is unlikely to be representative. It is more probably the case that we 
cannot yet be sure if there would be a significant increase in the cost of STI treatment as a result 
of the widespread availability of PrEP, though it is reasonable to suggest there would be an 
increase and thus it must be accounted for to some extent for an analysis to be externally valid. 
NICE notes cost-effective interventions may not be considered appropriate to provide where 
there is good reason, citing ‘significant limitations to the generalisability of the evidence for 
effectiveness’ (National Institute for Health and Care Excellence, 2008) as an example. 
Nonadherence will also play a role in the increased cost of STI treatment. Both nonadherence and 
risk compensation are dealt with fully in later chapters (see Chapter IV and Chapter V). 
 
Given the potential for community-level risk compensation (see Chapter V), it is also not simply a 
matter of an increased cost of STI treatment in PrEP users. Instances of STIs may increase among 
members of the MSM community who are not themselves on PrEP, or even those outside of the 
community14. This will further inflate the cost of STI treatment to be accounted for. However, 
 
14 STIs may spread outside of the MSM community via men who have sex with men and women (MSMW) 




again, it is difficult to determine if this will be significant. Despite the difficulty in determining this, 
sensitivity analyses in future studies ought to explore this. 
 
Following the increased cost of STI treatment is the increased cost of HIV treatment – or at least 
the lesser reduction in such costs. Whilst new instances of HIV will decrease overall, there may 
be some individuals who will contract the virus who would have been at less risk before PrEP. This 
would result in the HAART savings being less dramatic than expected. Such a phenomenon might 
come about when an individual previously at low risk of HIV infection suffers both nonadherence 
and risk compensation. This is discussed further in Chapter V, and it is unlikely to affect many, but 
it is again something to account for as it may contribute to PrEP moving further from being cost-
effective. 
 
As already highlighted, it is feasible that users will remain on PrEP for a period far longer than that 
assumed in economic analyses. Naturally, the longer an individual remains on PrEP the higher the 
cost. Whilst this is not necessarily an “associated cost” as it is the primary cost when considering 
PrEP provision, it may rightly be considered one where the assumption is that users will 
discontinue PrEP after an average of 4.5 years. Any drug costs after this time may at the very least 
be deemed “additional costs”. It is, then, vitally important that more thought goes into estimating 
the realistic cost of the drug itself so that it does not become both the primary cost and an 
additional cost in practice. 
 
The costs discussed in this section must all be borne in mind when considering the results of 
existing economic analyses of PrEP. There is, however, a question mark over each as to the extent 




of adherence and risk compensation in greater depth in an attempt to shed light on this, as well 




This chapter discussed limitations of a key existing economic analysis of PrEP. In assuming no risk 
compensation, good adherence, and an average of 4.5 years spent on PrEP by users, the 
Cambiano study is only internally valid and, as such, has limited use. This highlights the need for 
a study that starts from a better-informed foundation. 
 
I have touched on several potential issues with PrEP which would impact upon the cost-
effectiveness of the drug. These same issues raise ethical questions, which are the subject of this 
thesis. The following chapters explore them in greater depth, following the outlining of relevant 
ethical theory which is applied. Economic considerations are revisited in Chapter VII, supported 



































Ethical analysis in this thesis looks primarily to principlism, considering when autonomy might be 
justifiably overridden. All suggestions for the infringement of personal autonomy are assessed for 
proportionality, weighing harms and benefits beyond just the individual. It makes sense to set out 
relevant understandings of these concepts before application. I also address the question of 




Rather than looking to public health ethics, principlism is employed in this thesis due to the 
positioning of PrEP in the health space. The issues concerning PrEP that will later be explored are 
not strictly related to individual patient medicine, nor are they wholly public health matters. 
Principlism is a suitable choice given its flexibility in balancing conflicting values and thus more 
easily allowing consideration of harms and benefits to the individual, community, and wider 
population. Nonetheless I will draw on some ideas from public health ethics – particularly when 
considering proportionality – to complement the application of principlism. First, though, I will 
outline the understanding of principlism which guides this thesis. 
 
Principlism is an approach to medical ethics which utilises a framework of four ethical principles: 
(respect for) autonomy, nonmaleficence, beneficence, and justice (Beauchamp and Childress, 
2013). The principles are intended to be universally applicable rather than rooted in a particular 
cultural context (Beauchamp and Rauprich, 2016). This approach is based on the idea that a single 
principle cannot be suited to all real-world moral dilemmas and, as such, four are presented to 







Autonomy can be understood as ‘self-rule that is free from both controlling interference by others 
and from limitations, such as inadequate understanding, that prevent meaningful choice’ 
(Beauchamp and Childress, 2013). Myriad conceptions of autonomy exist, some more demanding 
than others. One demanding conception is that of Kant. For Kant, man ought to be bound by laws 
of his own making. This, prima facie, appears to fit with a colloquial understanding of autonomy. 
However, inclinations and emotional responses are considered external influences by Kant. 
Owing to Kant’s principle of universalisability, the autonomous individual does not act in a way 
that appeals to personal, non-intellectual factors; ‘the will is a capacity to choose only that which 
reason, independently of inclination, recognizes as practically necessary, i.e. as good’ (Kant, 
2011). This suggests that murder, for instance, cannot be an autonomous act as it would be based 
on the murderer’s personal inclination which cannot be universalised. In essence, the 
autonomous person under Kant’s conception is not autonomous at all by modern standards of 
personal autonomy, in part because it implies a standard of reason that may be unrealistic for 
some. As noted by Dawson, it is as a result of misreading Kant that one would conclude that he 
thought autonomy meant to do what one wants (Dawson, 2010). Further, Varelius notes that 
Kantian autonomy determines answers to questions such as the permissibility of euthanasia, 
whereas procedural accounts allow for greater flexibility as individuals might arrive at different 
conclusions (Varelius, 2006). Due to how demanding Kant’s conception of autonomy is – and 
therefore how unrealistic, in my view, it is – I will instead employ a more procedural conception 
of autonomy adapted from that of principlism’s authors, Beauchamp and Childress. Such a 
conception allows for autonomous action to be individualised, rather than resting on a 





Beauchamp and Childress present a conception requiring that three conditions are met: 
intentionality, understanding, and non-control (Beauchamp and Childress, 2013). Understanding 
and non-control are straightforward, and I will use them as outlined. Firstly, the individual must 
have an adequate understanding, given how impractical a standard full understanding is.15 
Adequate will be taken to mean an understanding of the key benefits and harms, demonstrable 
by the ability to explain these benefits and harms in one’s own words. This does mean that a 
single missing fact can result in insufficient understanding, particularly where it relates to a 
significant risk. Secondly, decisions and/or actions must be free of external control (with the 
important note that not all influences are controlling). The first condition – intentionality – I will 
revise. 
 
My issue with Beauchamp and Childress’ idea of intentionality is its binary nature; they hold that 
an act is either intentional or not. Further, they do not provide an outline of what they consider 
intentionality to mean, merely stating that ‘[a]cts are either intentional or nonintentional’ 
(Beauchamp and Childress, 2013). In the absence of a definition from Beauchamp and Childress, 
I will take intention to mean the agent’s act being directed towards their aim(s); an accidental act 
that fulfils the criteria of understanding and freedom from external control is not autonomous. 
They note that the conditions of understanding and non-control can be met ‘to a greater or lesser 
extent’, whereas an act is either intentional or not (Beauchamp and Childress, 2013). I suggest 
that there are levels of intention and that this condition may also be a matter of degree. To 
elaborate on this, I look to split-level theories of autonomy despite Beauchamp and Childress 
dismissing them. 
 
15 The idea of full understanding is problematised by Manson and O’Neill in the context of informed 
consent. They suggest that it may be too demanding to expect individuals to grasp complex scientific 
information (Rethinking Informed Consent in Bioethics, 2007). This is discussed in relation to participating 
in research, citing misunderstandings of research design such as placebos, but this point about the 




Dworkin presents the idea of first- and second-order preferences, whereby the autonomous 
individual’s second-order preferences allow critical reflection on his/her first-order preferences 
to either accept or change the latter (Dworkin, 1988). First-order preferences are our more base, 
instinctive preferences, whereas second-order preferences are more reasoned. The distinction is 
not necessarily a measure of quality – though in many cases higher order preferences may be 
deemed of higher quality – but is a note on the level of reason involved. Examples of higher and 
lower order preferences often relate to one another. For example, I may have the first-order 
desire to eat an entire tub of ice cream whilst contemporaneously having the second-order desire 
to not be obese. They do not necessarily sit in opposition, but it is where they do not align that is 
ethically interesting; we can question their interaction and set a threshold for autonomous action. 
 
Whilst this split-level theory still entails a binary result (i.e. one is autonomous or not), I will apply 
the idea of first- and second-order preferences to Beauchamp and Childress’ intentionality to 
afford it a spectrum. Thus, from stronger to weaker in terms of force exerted towards one’s aim16, 
an individual may act: 
 
(a) In accordance with both his/her first- and second-order preferences, where they happen 
to align 
(b) In accordance with his/her second-order preference and against his/her first-order 
preference, where the first-order preference was dismissed following critical reflection 
(c) In accordance with his/her first-order preference and against his/her second-order 
preference, where the first-order preference was pursued following critical reflection 
 
16 It is important to note that where first- and second-order preferences they misalign, each weakens the 




(d) In accordance with his/her first-order preference and against his/her second-order 
preference, where the first-order preference was pursued following negligible critical 
reflection 
 
Actions (c) and (d) are somewhat similar in that one has pursued his/her first-order desire against 
his/her second-order desire, but there is an important distinction in terms of the extent of critical 
reflection. Both would qualify as autonomous under Dworkin’s split-level theory as critical 
reflection has taken place. However, (d) is less autonomous as there is negligible critical 
reflection. Take, for example, a cheating spouse. The spouse has the first-order desire to cheat 
with someone based on a sexual attraction whilst simultaneously having the second-order desire 
to be faithful to his/her spouse and maintain a happy home life. A single instance of infidelity in 
the moment would constitute action (d) as there would likely still have been a brief moment of 
critical reflection and the act may result in a strong feeling of regret, whereas multiple instances 
would constitute (c) as the spouse has the opportunity to critically reflect to a greater degree 
over time. Therefore both (c) and (d) are autonomous acts of infidelity, but the level of 
intentionality is greater in (c) owing to the level of critical reflection involved. As such, (c) is a 
more complete expression of autonomy; this is, therefore, a more substantive conception of 
autonomy than that of Beauchamp and Childress, but still retains the procedural element and is 
not as problematically demanding as Kant’s autonomy. 
 
Given the importance of rational decisions in healthcare, only (a), (b), and (c) will be considered 
sufficient – assuming the criteria of understanding and non-control are met – for an action to be 
autonomous. As such, this is not an entirely procedural conception of autonomy as if it were, (d) 
would also be sufficient. Retaining the substantive element in deeming (d) insufficient is due to 




albeit a lesser expression of autonomy. Given the potential risks associated with PrEP which I will 
come to discuss, providing the drug following negligible critical reflection by the would-be user 
presents greater risks than benefits (this will be explored in later chapters). 
 
Autonomy, then, will be used in this thesis to refer to a hybrid of the Beauchamp and Childress 
model and that of Dworkin. Intentionality, understanding, and non-control are conditions that 
will all have to be met to deem an individual’s decision/action autonomous, and all three will be 
taken as matters of degree. Therefore, combining elements of both Kant’s substantive and 
Beauchamp and Childress’ procedural accounts of autonomy, the term “sufficiently autonomous” 
will be used where a decision/action sufficiently meets all three criteria. 
 
If individuals have a right to autonomy, there must be a corresponding duty to respect (and 
potentially facilitate) that autonomy. Mill’s harm principle holds that the autonomy17 of an 
individual ought to be respected by the state unless to prevent harm to others (Mill, 2006). For 
the general population, respect for autonomy can be characterised thusly – as a negative duty to 
not interfere except in extreme circumstances. In a healthcare context, a more demanding 
account of ‘respect’ is needed, which requires medical actors18 to actively facilitate the ability of 
individuals to exercise their autonomy. For a patient to make an autonomous decision in the way 
I have outlined, it is necessary for medical actors to enable understanding. Beyond simply an 
ethical requirement, this was ruled to be a legal requirement in the case of Montgomery v 
Lanarkshire Health Board 2015. As such, medical actors should be providing necessary 
information, including alternative options. For example, a drug might be offered in both pill and 
 
17 Mill wrote specifically about ‘individual liberty’. 
18 Medical actors can be taken to include clinicians as well as those responsible for commissioning decisions, 




capsule form so that the patient is able to choose the option that best suits them. To offer only 
one option creates a binary decision between taking the drug and not which, depending on the 
nature of the treatment, might prove coercive as a patient cannot reasonably say no. Of course, 
this does have to be within the parameters of clinical feasibility, so some options will have to be 
binary. 
 
Principlism is often criticised as an approach for the primacy it places on autonomy. Indeed, Gillon 
refers to the principle as ‘first among equals’ (Gillon, 2003). Whilst an oxymoron, such a position 
appears to have been cemented since Beauchamp and Childress first coined the quartet. 
Nonetheless, there is opposition to the prioritisation of autonomy. For example, appealing chiefly 
to autonomy might sometimes result in supporting what is known to be beset with problems. 
Dawson argues this point, presenting the example of advanced directives which may respect 
patient autonomy but are also known to be problematic for other reasons (Dawson, 2010). 
Dawson’s point is particularly pertinent in this thesis as will later be demonstrated. Some 
advocate instead for a more balanced principlism (Callahan, 2003; Lepping et al., 2016). It is, in 
fact, not uncommon for proponents of autonomy’s pole position to inadvertently support a more 
balanced principlism themselves. One such example is Gillon, who argues respect for autonomy 
must be qualified by respect for the autonomy of all potentially affected persons (Gillon, 2003). 
A consideration of the autonomy of all who might be affected falls more into an idea of justice. 
Dawson, therefore, advocates value pluralism, noting that values other than autonomy are as 
important and that in some situations they ought to take precedence (Dawson, 2010). This thesis 
will employ a balanced principlist approach, giving fair consideration to the other three principles: 







The principle of nonmaleficence is rooted in the Hippocratic tradition of Primum non nocere. 
Nonmaleficence is the idea that the work of a doctor is not to harm the patient and is thus a 
negative obligation. A harm is understood as an adverse effect on the interests of X (Beauchamp 
and Childress, 2013). However, harmful actions in themselves are not necessarily wrong and can 
be justified if they are performed in order to bring about greater benefit that serves the patient’s 
interests, such as the amputation of a gangrenous limb. In actuality, then, nonmaleficence is more 
the avoidance of harm in the absence of appropriate justification. Factoring in harm is essential 
in decisions about the provision of drugs such as PrEP, as side effects – medical and otherwise – 
can be significant enough (as I will demonstrate) to bring into question the importance of 
respecting an individual’s autonomous decision to take the drug. 
 
Given the potential for PrEP to harm those beyond the individual taking the drug (see Chapter V) 
nonmaleficence must also be considered at the population level. It will then become a trade-off 
between lesser and greater harms to the individual and the population (Schroder-Back et al., 
2014). Here the flexibility of principlism, and thus my reason for choosing such an approach, is 
apparent. It can apply to decisions with very clear implications for both individuals and 




Beneficence and nonmaleficence are often conflated. Frankena, for example, includes an 
obligation ‘not to inflict evil or harm’ (clearly nonmaleficence) as part of his conception of 




in that nonmaleficence is general whereas beneficence is more specific; we ought not to harm 
anyone, whereas our duty to do good only applies in relation to some people (Gillon, 1985).   
 
I agree with Beauchamp and Childress – and Gillon – that to combine beneficence and 
nonmaleficence into one principle is problematic, and so beneficence is taken as a positive 
obligation to contribute to the welfare of the party concerned (Beauchamp and Childress, 2013). 
It has no greater importance than nonmaleficence, nor lesser. It simply requires that the medical 
actor do what improves the welfare of a patient unless a suitably strong reason against that 




Of the four principles, justice is the one I am least concerned with in this thesis, though it does 
act as a backdrop. As already highlighted, there is a major question of cost-effectiveness with 
PrEP that I have demonstrated is not yet answered. However, I do not wish to focus on questions 
of resource allocation. The financial complexities of PrEP provision require thorough economic 
evaluation prior to an ethical appraisal, so this will not be discussed. 
 
The extent of engagement with the principle of justice in this thesis is the application of the other 
principles at both the community and population levels. As such, it is a distributive justice 
approach – as outlined by Beauchamp and Childress (Beauchamp and Childress, 2013) – that I 
will employ in relation to the right of all citizens to health. Thus, where the actions of one would 
infringe upon this right in others, reasonable means of preventing that action are justified.19 
 




Justice, then, is appealed to in beneficence and nonmaleficence, as well as the autonomy of those 
other than the (potential) PrEP user, justifying the infringement of autonomy; it is a matter of 
avoiding an undue and disproportionate burden to others for the benefit of a few. Therefore, 
justice will not often be explicitly mentioned, but will be an implicit factor in the community- and 




As earlier stated, I will be using a balanced principlism, whereby no single principle automatically 
dominates. Far more has been said about autonomy than any other, but this should not be taken 
as an indication of greater importance. Rather, it is due to the complexity of the principle and the 
wealth of conflicting literature on it compared to the others which necessitates lengthier 
engagement. 
 
In addition to the criticism of principlism’s focus on autonomy, the approach is often criticised for 
failing to provide action guidance. Notably, Clouser and Gert argue that the four principles merely 
provide ‘headings for a discussion’ (Clouser and Gert, 1990). Contra this, I suggest one of the 
benefits of principlism is the flexibility this permits. Blindly following a predefined theory is 
problematic, as is apparent in several thought experiments relating to, for example, 
utilitarianism.20 Instead, principlism provides important points of reference for a consideration of 
the most appropriate course of action whilst also allowing for the incorporation of other 
complementary principles, examples of which I will now discuss. 
 







In the arguments that follow, where suggestions are made that patient autonomy be deprioritised 
in favour of either beneficence or nonmaleficence, I make an important distinction between 
coercion and withholding. The foundations of this distinction are built on ideas of bodily integrity. 
 
The coercion-withholding distinction holds that forcing an intervention or treatment upon an 
individual is generally harder to justify than withholding it.21 For instance, forcing a patient to 
undergo dialysis without consent is significantly harder to justify than refusing to start a patient 
on dialysis at their request. It is important to note that this distinction is only intended to apply 
to interventions and treatments which are already sanctioned by a suitable authority.22 As such, 
criticism based on examples such as starvation (withholding) being more easily justified than force 
feeding (coercion) do not undermine this distinction, because starvation is not an approved 
treatment/intervention and thus does not fall within the boundaries of the distinction. 
 
The basis for this distinction is respect for bodily integrity. Its relevance is nicely summarised by 
Herring and Wall: ‘giving a patient treatment they do not want is interfering with not only their 
autonomy but also their right to bodily integrity. Whilst refusing treatment to a patient who 
wishes it is interfering in their autonomy alone’ (Herring and Wall, 2017). In following this 
distinction, I look to Feldman’s definition of bodily integrity as ‘a right to be free from physical 
 
21 The thought process behind this distinction was prompted by a discussion of active and passive 
paternalism in Michael Ardagh’s Paternalism to autonomy and back again (1998). 




interference’(Feldman, 2002). This, notes Feldman, encompasses negative liberties against acts 
such as physical assault and degrading treatment (those being the most relevant to this situation). 
 
In interfering with a greater number of rights, coercion necessitates a higher level of justification. 
However, withholding still frustrates autonomy so requires suitable justification. Justification 
arises when an intervention or treatment causes more harm than benefit.23 Returning to the 
dialysis example, consider a patient with kidney failure for whom dialysis has been considered. 
The medical team conclude the patient will not clinically benefit from dialysis due to the poor 
prognosis arising from multiple comorbidities, though the patient insists (s)he wants to try it. The 
harms associated with dialysis are significant: extensive side-effects, necessary lifestyle changes 
to conform to demanding treatment, as well as increased risk of, for example, anaemia, sepsis, 
and hernia. Given the comorbidities of the patient in question, there are greater risks. In this case, 
then, the harms of undergoing dialysis are greater than the benefit as the benefit is limited to 
satisfying the request of the patient (because the medical team have determined that there is no 
clinical benefit). Even when psychological harm to the patient caused by refusing to start them 
on dialysis is considered, withholding the therapy is still less harmful overall. Therefore, 
withholding dialysis may be justified in this scenario as there is minimal insult to autonomy. Such 
a scenario would be appropriately categorised under (c) or (d) in terms of the intentionality 
criterion of autonomy earlier outlined, as the first-order preference for health and the second-
order preference to be dialyzed do not align, and critical reflection will have taken place but it 
may have been negligible. 
 
 
23 I acknowledge that this is paternalistic action, though I have not framed it as such. This thesis is, as 
outlined, framed in terms of principlism. I have therefore avoided the use of the term “paternalism” as 




Withholding might further be justified by considering the integrity of medical practice. Doctor’s 
ought not to be compelled to provide an intervention they deem inappropriate or futile (Jecker 
and Schneiderman, 1993), and there is a risk of moral distress if such an expectation were to be 
placed upon them (Jameton, 1984). Thus a limit to autonomy exists in the patient having ‘the 
right to refuse treatment, but not to demand it’ (Herring and Wall, 2017). Herring and Wall 
provide the example of cosmetic surgery, whereby a patient indeed has the autonomous right to 
refuse such surgery, though a patient has no guarantee of such surgery being made available if 
sought through the NHS. To protect the integrity of medical practice and the health of the patient, 
it is important to permit this degree of limitation in the decision about what options are made 
available to the patient, thereby permitting the previously discussed binary option between 
treatment or no treatment in some circumstances based on clinical discretion. 
 
It is important to note that the distinction does not hold that withholding is easily justified. Rather, 
it is easier to justify than coercion because of the lesser insult to autonomy in that it does not 
disregard bodily integrity. In some instances, withholding will be unjustifiable, whilst in others 






In considering interventions, an important factor is proportionality. For an intervention to be 
proportionate, the relationship between the ends and means must be ‘appropriate’ (Hermerén, 
2012). Much like a harm-benefit calculation, the outcome sought must be sufficiently beneficial 
to outweigh whatever harm the intervention brings (for instance, an insult to autonomy). 




arguing the essentiality of ‘the probable public health benefits outweigh[ing] the infringed 
general moral considerations’ (Childress et al., 2002). In that sense, proportionality can be viewed 
as both normative and methodological (Schroder-Back et al., 2014). 
 
Proportionality speaks to an innate feeling of justice, ensuring that collateral damage is limited in 
pursuit of health goals. Interestingly, Childress and colleagues consider ‘[l]east infringement’ an 
altogether separate moral consideration (Childress et al., 2002). I do not see this distinction as 
useful and, rather, believe that the idea of minimising infringement is encompassed by the 
principle of proportionality. As such, I look to Hermerén’s characterisation of the principle as 
quad-conditional (Hermerén, 2012). 
 
Hermerén first outlines three conditions he draws from the European Group on Ethics – (1) the 
importance of the intended goal, (2) the relevance of the means to achieving that goal, and (3) 
that means being the most favourable (i.e. no less controversial means is available) – before 
providing a fourth in ‘[n]on-excessiveness’ (Hermerén, 2012). This fourth, important, condition 
requires that when a certain means fulfils conditions (1), (2), and (3) it still should not be 
excessive; an end can be disregarded if the means of achieving it is excessive. To illustrate this 
Hermerén provides the example of an old man in a wheelchair who is at home alone and observes 
a boy stealing apples from his tree, before shooting at the boy with his gun (Hermerén, 2012). 
The goal of preventing theft is important, shooting the boy is likely to be successful in that regard, 
and there are no feasible alternatives. However, it is reasonable to assert that to shoot a child is 
an excessive way of preventing the theft of a few apples. The importance of this fourth condition 
is where the principle of proportionality in its academic sense aligns with proportionality in its 








PrEP, much like the BCP, can sexually liberate users. It is important to address the role I see sexual 
liberation taking in policy decisions such as PrEP and pre-emptively deal, here, with objections to 
later conclusions. 
 
The World Health Organization (WHO) notes the importance of ‘the possibility of having 
pleasurable and safe sexual experiences’ in its definition of sexual health (World Health 
Organization, 2015) which PrEP is said to provide (Mabire et al., 2019). However, the WHO 
definition also notes that ‘[f]or sexual health to be attained and maintained, the sexual rights of 
all persons must be respected, protected and fulfilled’ (World Health Organization, 2015). In 
relation to my earlier discussion of justice, this is why I adopt a position of the primacy of 
physiological health. Sexual liberation being integral to a “healthy” sex life is important, but how 
broad this conception of liberation ought to be is a moot point, especially – as will be shown in 
later chapters – when the pursuit of such liberation comes at a cost to the health of others. 
 
Sexual liberation is important to the point that, provided all parties consent, people should be 
free to have sex with who they want and when they want. However, it should be the responsibility 
of these individuals to take reasonable precautions to protect themselves from health risks 
associated with sexual activity, such as HIV and other STIs. Such precautions include sexual health 
screenings when appropriate24 and condoms, again when appropriate.25 These being easily 
 
24 Regular sexual health screenings are advised for those who are regularly engaging in sexual activity with 
new partners. Those in closed, long-term relationships have little to no need for them. 
25 Whilst the use of condoms or another barrier method (such as a dental dam) is recommended for vaginal, 




available fulfils the WHO point about safe sexual experiences. Indeed, in keeping with the earlier 
outlined conception of respect for autonomy, medical actors ought to ensure the provision of 
these options. However, whilst PrEP can be seen as fulfilling it further, it equally – as will be 
demonstrated in later discussion – infringes upon the other important aspect of the WHO 
definition. 
 
CAS with an individual whose sexual health status you are unsure of is, in a medical sense, 
objectively unhealthy as it presents a risk to one’s own health and, taken further, the health of 
others if you were to become infected and later pass that infection on. This is discussed in greater 
depth later in this thesis, but for now I will note that the importance of enhanced sexual freedom 
and enjoyment PrEP might afford users is not, to my view, more important than physiological 
health and the protection of those beyond the users from infection. A full discussion of the 
relevance of sexual liberation to such decisions constitutes a debate in its own right, and 
constraints on space prevent me engaging fully with this debate. As such, this thesis will proceed 





The theoretical positions outlined in this chapter will be applied throughout this thesis. This initial 
overview will act as a useful point of reference and remove the need for repetitive background 





This chapter has also demonstrated the relatively low importance ascribed to sexual liberation in 
this thesis. As criticism is anticipated on this basis, this has been important in establishing the 






































The key factor differentiating efficacy and effectiveness with PrEP is adherence. Only users who 
fully adhere to the drug as instructed experience the level of protection from HIV infection they 
are likely expecting. There are potential ethical issues in providing PrEP if users struggle with 
adherence. 
 
If PrEP users are expecting effectiveness of 90% or more, but struggle to maintain full adherence, 
there is a disconnect between expectations and reality in protection from HIV. Whilst users would 
be informed of the importance of adherence and the potential consequences of missing doses 
(particularly if coupled with risk compensation), it is perhaps unrealistic to expect sufficient 
acknowledgement of the risks. It seems likely some users will assume missing the occasional dose 
will not make a difference, and/or human error will result in some missed doses. 
 
It is necessary to initially consider the differences between available dosing options. I explain the 
main two – daily and event-based – as well as a third, less common option of so-called Ts and Ss. 
Following this, I focus predominantly on daily usage for reasons which are explained. 
 
To consider the extent to which we can expect full adherence from PrEP users, I look at indications 
in existing PrEP studies. There are reasons to expect lower adherence in real life, which I expand 
on in my discussion, but we can still learn from these trials. I also consider adherence to both PEP 
and the BCP; there are useful parallels which make them more useful to consider than, say, 
adherence to antibiotics. 
 
After establishing likely adherence to PrEP, I consider ethical implications. Where nonadherence 




not at the level expected by the user as a result of nonadherence, there is the potential for harm. 
This is the case particularly where nonadherence is experienced alongside risk compensation (see 
Chapter V). I first demonstrate that nonadherence at a level where PrEP is overall causing more 
harm than good can justify denying access to PrEP, before qualifying that with the fact 
nonadherence to that level is unlikely. I then argue for appropriate action to assist in minimising 
PrEP nonadherence. This is justified in terms of effectiveness and proportionality in overcoming 
the increased risk and resulting harm introduced by nonadherence. 
 
Finally, an overview of the future of the administration of PrEP is provided. Where the 
requirements on the individual are reduced (i.e. no daily pill) the chances of nonadherence will 
be reduced. This may overcome some of the ethical challenges. I consider current research into 
LAI-PrEP and how its introduction may affect ethical issues in PrEP provision. This includes a 
proposal of LAI-PrEP as the default option, looking to beneficence as justifying reduced options. 
 
I begin by detailing the current options for the use of PrEP and outlining how their differences 




There are currently two main options for PrEP administration; daily and event-based (also known 
as on demand). Daily usage is straightforward – users take one dose each day, much like the BCP 





Event-based usage is less straightforward. It requires users to anticipate CAS and take a double 
dose of PrEP 24 hours before, then two further doses, one 24 hours later and another 48 hours 
later (Umbrella, 2017). This approach is unlikely to be suitable for many. Sex is often unplanned, 
particularly CAS. It is also possible sex may be anticipated with the intention of using a condom, 
only for the condom to be forgotten at the last minute, or even to break and for the individuals 
concerned to continue without a replacement – if this happens then event-based PrEP offers no 
protection. There is a risk with event-based usage that individuals will find themselves engaging 
in CAS when not protected, simply because they have not anticipated such an occurrence. 
Nonetheless, event-based dosing was used in the IPERGAY study (Molina et al., 2015). 
 
A third approach is Ts and Ss. This method requires four doses each week, on days starting with 
either T or S26 (I Want PrEP Now c). Those opting for this method are advised to complete an 
initial week of daily dosing, before dropping down to four per week. The theory behind this 
method is that those not frequently engaging in CAS do not need a high concentration of the drug 
in their blood, and four pills each week will be enough. This is problematic because the lower the 
concentration of the drug in your body the lesser the protection from HIV it provides. Further, it 
is realistic to assume some users would suffer nonadherence as it is an unusual routine to get 
into27. 
 
It is understandable why Ts and Ss came about, as it is aimed at those purchasing PrEP 
themselves. The cost of PrEP out-of-pocket can be prohibitively expensive, so Ts and Ss aimed to 
almost half the cost. By spacing out dosing and increasing the frequency at the weekend28, it 
 
26 Tuesday, Thursday, Saturday, and Sunday. 
27 There is no data on adherence to Ts and Ss. 





intends to maintain a drug concentration that is hoped to be enough to protect against HIV. It is 
an “anything is better than nothing” approach, which is potentially troubling as users may not 
sufficiently recognise that the level of protection they are receiving is reduced compared to daily 
PrEP. The Ts and Ss method is not widely acknowledged, though warrants a mention. 
 
Daily usage is considered the best option because not only does it maintain drug levels, but also 
makes adherence easier. It is for this reason I mainly consider daily usage throughout this chapter, 




Studies of PrEP adherence are limited but results from PrEP trials can be useful in providing early 
indications of the reality if the drug were made widely available. However, any findings are to be 
taken cautiously as higher adherence is to be expected in trials than in real world conditions 
(Osterberg and Blaschke, 2005). 
 
Findings from the iPrEx study provide useful information on the potential impact of side effects 
on PrEP adherence (Grant et al., 2010). Self-reported pill use in the PrEP group versus the placebo 
group was lower at week 4 and at week 8 (though the difference was smaller at week 8) but was 
similar from then on. Given the fact that side effects of PrEP are experienced in the first few weeks 
before subsiding, it is very possible that this difference in adherence is a result of some of the 





According to Gilead29, 7% of PrEP users experience headaches and 4% suffer abdominal pain 
(Gilead Sciences). It is not clear whether these side effects would be severe enough to cause 
nonadherence in a significant number of users, but it is possible. Further, these minor and 
common side effects arise in the first few weeks of PrEP usage before subsiding in the few weeks 
following, making it important that new users are aware of this and do not think they will persist; 
failure to provide such information could result in premature discontinuation. 
 
The IPERGAY study is useful in demonstrating why event-based usage presents adherence 
difficulties for users (Molina et al., 2015). This study looked at MSM at high risk of HIV infection 
and their usage of event-based PrEP. Not only did 29% of participants take their assigned drug at 
a suboptimal dose, but 28% did not take it at all. Therefore, only 43% of participants took the 
drug as instructed. This level of nonadherence is worrying and, if found in practice long-term, 
would undermine the purpose of PrEP provision. This nonadherence may have been because the 
study was looking at event-based PrEP, so there was no routine for participants to get into. The 
importance of routine for adherence is discussed later in this chapter. 
  
As previously mentioned, adherence findings from PrEP trials are not entirely reliable. This is due 
to the likely characteristics of participants. Trial participants are more likely to engage in health-
seeking behaviour; to choose to enrol in a trial and fulfil the associated obligations suggests 
greater interest in health and a desire to see advancements in HIV prevention and care, meaning 
trial participants are more likely to focus on adherence. There is, though, a chance this would be 
countered by the fact that participants’ knowledge that they could be receiving a placebo may 
cause nonadherence. 
 




Trial participants are also likely to be more confident about their sexuality and lifestyle; it seems 
unlikely an individual uncomfortable with their sexuality or ashamed of their lifestyle would enrol 
in a trial which they are eligible for based on their sexuality and lifestyle. PrEP use comes with a 
certain amount of social stigma (Calabrese and Underhill, 2015), which may cause MSM who are 
less confident and therefore less able to ignore it to question their use of the drug, and thus have 
issues with adherence. 
 
Finally, there is the fact self-reporting is the most frequently used measure. This is an inherently 
unreliable means of ascertaining adherence, though is still common in health monitoring. 
Problems with self-reporting are explored in Chapter VI. 
 
These studies suggest some issues with adherence may be experienced, particularly with event-
based usage of PrEP. However, results are mixed. Further findings are needed, which may come 
as a result of the PIT. Meanwhile, we can look to evidence of adherence to drugs with similar 
obstacles for users. 
 
Lessons from post-exposure prophylaxis 
 
PEP adherence may provide useful insights into expected adherence to PrEP because both are 
aimed at the same population group(s) and utilise the same drugs. 
 
A systematic review and meta-analysis in 2014 assessed adherence to PEP, including 97 studies 




poor. The broad nature of this review means the average completion rate of 56.6% includes 
various populations, however when broken down we find that still only 67.2% of MSM completed 
the full course. Whilst this is higher than the average, it is still poor given the severity of the 
scenario PEP is used in. A number of these discontinuations will be attributed to the discovery 
that there was no exposure to HIV, but only a small number30. If similar adherence was found 
among PrEP users, it would undermine the purpose of making the drug available as users would 
not be significantly protected from infection as intended. 
 
Another study, where 83% of patients were MSM, found only 4% discontinued PEP (Thomas et 
al., 2015). However, 16% were lost to follow-up. It is reasonable to assume that of patients who 
failed to attend follow-up, a significant number may have been nonadherent; if you are fearful of 
HIV and have identified a risk of infection, then complete a course of PEP, you would likely attend 
a follow-up to seek assurance that you have not become infected. Further, with this study 
measuring adherence by self-reporting it is likely that, accounting for social desirability bias, the 
rate of discontinuation was higher than reported. Regardless of the extent of discontinuation, this 
study is useful in also telling us 70% of those who failed to complete the full course of PEP cited 
side effects as the reason (Thomas et al., 2015). This is important as there are side effects 
associated with PrEP use, as already highlighted, which would be the same as those experienced 
by users of PEP. 
 
Evidence varies, but findings concerning PEP do suggest some level of nonadherence is to be 
expected of PrEP, as well as some discontinuation. Even if discontinuation were as low as 4% this 
would still be a noteworthy issue – at the very least, it would be important to explore the reason(s) 
 
30 A guaranteed negative HIV test is not possible within 28 days of exposure. Finding out there was no 




for discontinuation. This would present a potential ethical objection to the provision of PrEP, 
suggesting the risk of nonadherence would need addressing if PrEP were to be made widely 
available. 
 
Lessons from the birth control pill 
 
Parallels are consistently drawn between the BCP and PrEP (Myers and Sepkowitz, 2013). The two 
most common issues raised with both are risk compensation (see Chapter V) and adherence. In 
terms of adherence, the BCP is similar to PrEP in that its effectiveness is directly related to 
consistent and correct use (Moreau et al., 2006). Concerns were raised when the BCP was 
invented that women would struggle to adhere to the prescribed daily pill, particularly those from 
poorer/uneducated backgrounds (Myers and Sepkowitz, 2013). It makes sense, therefore, to 
assess BCP adherence and consider whether lessons might be learned. 
 
There is much variation in reported adherence between studies. Findings of women missing at 
least one pill each cycle range from 20% (Moreau et al., 2006) to 52% (Molloy et al., 2012), with 
women missing two or more ranging from  7% (Moreau et al., 2006) to 22% (Rosenberg et al., 
1998). These studies are from different countries, and indeed different decades, which explains 
some difference in findings. What is clear, though, is that nonadherence is prevalent. Even by the 
lowest figures, 20% of women missing one pill each cycle and 7% missing two or more is not 
insignificant. It is nonadherence that results in the failure rate of the BCP during typical use being 





An emerging theme in BCP adherence is routine. Studies find women without a fixed time each 
day when they take the pill are far more likely to have some level of nonadherence (Rosenberg 
et al., 1998; Molloy et al., 2012; Moreau et al., 2006). One UK study found 90% of those who 
never missed a pill had a routine, whereas only 44% of those who missed two or more each cycle 
did (Molloy et al., 2012). This reflects earlier findings in the USA that lack of a routine suggests a 
woman is more likely to miss two or more pills each cycle (Rosenberg et al., 1998). If this were 
the case with PrEP, efforts would be needed to get users into a routine to aid adherence. 
 
Unpleasant side effects have also been found to cause nonadherence to the BCP (Moreau et al., 
2006). A similar effect has been observed in HIV+ individuals who are on HAART (Ammassari et 
al., 2001), as well as those using PEP as discussed earlier. This is, as already highlighted, a potential 
concern with PrEP as the drug has common side effects.  
 
Considering findings concerning adherence to the BCP, it is again important to keep in mind the 
risks associated with self-reporting. One study looking at BCP adherence found a significant gap 
between women’s reporting of their adherence and the reality (Potter et al., 1996). It is possible 
adherence to the BCP is worse than is suggested by the studies referenced. 
 
It is evident some women struggle to maintain full adherence to the BCP for a variety of reasons. 
Common reasons are lack of routine and side effects, which are issues that may foreseeably arise 
with PrEP. We can, then, approach PrEP policy having learned from the experience of the BCP by 
attempting to minimise the impact of these factors on adherence. This would help minimise 





Ethics surrounding nonadherence 
 
It is, based on early studies of PrEP adherence, and the reality of PEP and the BCP, realistic to 
expect nonadherence to PrEP which may lead to increased risk of HIV infection in some users 
and/or affect the reduction of the risk of infection in the wider community/population. This raises 
ethical concerns to address prior to PrEP becoming widely available. The relationship between 
autonomy and both nonmaleficence and beneficence is key if making PrEP unavailable due to 
adherence issues is considered, or if any intervention(s) which may compromise the user’s choice 
are proposed. 
 
The first issue is the impact of nonadherence on PrEP’s effectiveness. If a user is not fully adherent 
to PrEP, he will not experience the maximum protection it can provide and which he may expect. 
Healthcare staff would inform users of the dangers of nonadherence, but the extent to which this 
information would be sufficiently understood and followed is in doubt. This results in a potential 
disconnect between user expectations and the reality of PrEP’s effectiveness. Those seeking PrEP 
may already believe it cannot fail due to the positivity attached to word-of-mouth and online 
promotion within the MSM community (I Want PrEP Now b), which is itself an issue, but as 
nonadherence causes effectiveness to drop the disparity between the patient’s beliefs about the 
effectiveness of the therapy and the reality will grow assuming expectations are unchanged. This 
may be worsened if risk compensation also arises in a nonadherent user; with the effectiveness 
of PrEP dropping due to his nonadherence, and the risk of HIV infection increasing due to risk 
compensation, the gap between expectation and reality grows yet further. If this were to result 
in the effectiveness of the drug being compromised to the point that the intervention does more 





This would be a proportionate denial of the prospective PrEP user’s autonomy based on ‘a defect 
in their decisionmaking [sic] that leads them to engage in self-harming activity’ (Buchanan, 2008). 
‘Defect’ may seem an overly harsh term, but if a PrEP user were to be nonadherent, this would 
not likely be a sufficiently voluntary decision. Human error is the main reason for this 
nonadherence. Whilst the user might recognise that he is occasionally missing doses and think 
nothing of it, he may not, at the time he is due to take his daily pill, be making an active decision 
not to as the thought may not cross his mind. As for users who may miss doses because of side 
effects, this too cannot be considered a sufficiently voluntary decision; the unpleasantness of the 
side effects may partially impair judgement as the individual may not be thinking through their 
decision in terms of weighing up the side effects and the potential health impact of missing doses, 
and they may not sufficiently understand the risks of nonadherence. As this nonadherence would 
be a non-voluntary decision, to deny access to PrEP would not be imposing a view of the good 
which is against that of the individual. In fact, it would be entirely consistent with the good they 
have chosen for themselves – the avoidance of HIV infection (second-order preference) – which 
this would seek to support; in terms of intentionality, such an individual would be acting in 
accordance with classification (d) as negligible critical reflection is taking place (see Chapter III). 
 
Even if this nonadherence were considered sufficiently autonomous, it is important to remember 
autonomy is not the sole focus of ethical healthcare provision. There is no necessary reason to 
prioritise autonomy over other ethical values (Lepping et al., 2016). In this case, nonmaleficence 
permits the denial of PrEP access and the potential harms to the would-be user are great enough 
that respect for his insufficient autonomy can be denied. In balancing ethical priorities, denying 
potential users PrEP to prevent potential harm is not a significant enough insult to autonomy as 
to undermine the justification. Further, it is a matter of not introducing a new intervention rather 




widely available would require greater justification (see Chapter III). If nonadherence results in a 
significant drop in the effectiveness of PrEP, then, it would be justified to deny access to the drug. 
 
However, missing the occasional dose, provided it is not consistent, will not drastically reduce the 
effectiveness of PrEP. For the effectiveness to drop to the point where the user’s risk of HIV 
infection becomes clinically concerning, adherence would have to be very poor – i.e. consistently 
missing multiple doses each week. This is unlikely to be the case for many users. Therefore, 
occasional missed doses when a user is on a programme of daily PrEP is to be discouraged but is 
not clinically problematic so does not alone justify the denial of access to PrEP on the basis of 
nonmaleficence.  
 
That does not, however, mean efforts should not be made to prevent/minimise nonadherence, 
as there is potential for nonadherence to lead to discontinuation over time. Eventual 
discontinuation presents a more poignant concern. 
 
If a user becomes nonadherent to any extent, it is possible he will struggle with adherence more 
over time, potentially discontinuing the drug entirely or becoming nonadherent to an extent that 
he is afforded is minimal protection. Whilst this is not itself problematic, if coupled with risk 
compensation (see Chapter V) there is potential for that user to be at a greater risk of HIV 
infection after discontinuing PrEP than he was before he began taking the drug. 
 
Risk compensation is considered in Chapter V, but for the purposes of this discussion it is the 
phenomenon whereby a PrEP user begins to engage in riskier sex as a result of his perceived 




the extent of entirely abandoning condom use. Once this response to PrEP has taken place, 
whether intentional or not, it is not reasonable to expect it to be reversed. Once an individual is 
out of the habit of using condoms, it may be difficult for him to revert and stop engaging in risky 
sexual practices after discontinuing PrEP; this is nothing to do with perception of or concern about 
risk, but simply difficulty in changing habits. Such users will no longer be receiving the protection 
of PrEP whilst engaging in riskier sexual practices, putting them at greater risk of HIV infection 
than before they commenced with PrEP, in addition to an increased risk of STIs. 
 
For similar reasons to those discussed in relation to occasional nonadherence earlier in this 
chapter, some form of intervention is justified in this situation. The increased risk caused by 
eventual discontinuation is likely to result in harm to some users, thus justifying action to remove 
this risk even if compromising autonomy. In determining the appropriateness of a potential 
intervention, proportionality is vital (Childress et al., 2002). To deny access to PrEP is not a 
proportionate response here, or at least not as a first response. This is because it should be 
possible to flag users who are heading in the direction of discontinuation and provide necessary 
support as prevention. If effective methods can be introduced to prevent nonadherent users 
reaching the point of discontinuation, there is no reason why PrEP cannot be made available – at 
least in terms of adherence concerns – because the harm that could arise is prevented. 
 
All users will have the importance of adherence explained to them before receiving PrEP, but this 
is insufficient. As highlighted, nonadherence is not always entirely intentional, but, rather, 
something that can happen as life gets in the way. It is vital safeguards are in place to flag 
nonadherence early and address the issue before discontinuation occurs, as the potential harm 
of discontinuation is generally preventable so allowing it is a failure to respect the principle of 




user, establishing a fixed daily time to take the drug. Whilst this routine cannot be enforced, 
telling a potential user he must take the pill at a fixed time rather than presenting it as best 
practice is a good starting point. This may be perceived as acting against the user’s autonomy to 
the extent that it is trying to impose a routine, but this is justified both because it is a very minor 
infringement and because lack of routine is a significant cause of nonadherence; ergo, it is an 
instance of beneficence which is also proportionate. Establishing routine is in the user’s interests 
even if inconvenient, and the potential harm he could be exposed to without routine is greater 
than this trivial infringement of autonomy. Autonomy would be respected to the extent that the 
user would be party to establishing a suitable time each day, but the imposition of routine is both 
in the interests of the individual user and the wider population and is therefore justified in terms 
of both nonmaleficence and beneficence.  
 
Initial consultations could consider research on personality traits that have been shown to be 
both negative and positive predictors of adherence behaviour, which would allow healthcare staff 
to identify users who may benefit from additional support in establishing good adherence 
(Axelsson, 2013; Axelsson et al., 2011; Munro et al., 2007). A randomised controlled trial of an 
SMS service to support PrEP adherence in Chicago has shown promising results (Liu et al., 2018), 
presenting an option for all users rather than just those most likely to struggle. Those receiving 
PrEP should also be monitored for adherence so healthcare staff can intervene as soon as possible 
to prevent discontinuation. SMS reminders and user monitoring are minimally invasive additions 
to PrEP provision, representing nudges at most. They are justified both in the interests of 
individual PrEP users and the wider population, as they have the potential to remove harm 
without significantly denying users their autonomy; if they insulted autonomy to a greater degree 





With processes for establishing and monitoring adherence, as well as addressing problems early, 
ethical issues arising from nonadherence can be minimised to the point that they are no longer 
obstacles to the provision of PrEP. Therefore, nonadherence does not present significant enough 
ethical barriers to deny access to PrEP provided additional means of supporting users which 
restrict autonomy only to a proportionately small degree are introduced. 
 
My focus thus far has been on daily usage as it is the best method, though it is worth briefly noting 
ethical issues surrounding other usage options. With both event-based usage and Ts and Ss, the 
issues are similar to those with daily, though more acute; if a user opts for one of these dosing 
options over a daily pill, the potential for nonadherence is far greater. Event-based usage does 
not allow a user to benefit from routine at all, and the sporadic nature of the Ts and Ss routine is 
such that users are far more likely to be nonadherent to this option than daily dosing. 
 
For these other dosing options, the same remedies would be suitable and with the same 
justifications. There is, however, one further issue that stems from these two approaches. That is 
in the user’s consultation with healthcare staff ahead of starting PrEP. It would be ethically 
questionable for healthcare staff to present any option other than daily dosing in the first 
instance. 
 
Offering only daily dosing is a greater infringement of autonomy than previous suggestions, as it 
denies the user a choice. However, specifying instructions for the taking of prescribed drugs is 
standard practice. We are not given an option as to how frequently we take doses of a course of 





There is a risk the lack of choice will discourage some potential users who would benefit from 
PrEP. Some may feel event-based usage is more suitable if they only occasionally engage in risky 
sexual practices, and denying them this option may discourage them from accessing PrEP 
altogether. However, this infringement of autonomy is justified on the bases of both 
nonmaleficence and beneficence due to the increased likelihood of nonadherence with event-
based usage and Ts and Ss. Allowing a user to choose one of these other dosing options is to open 
him up to potential harm when he may not sufficiently acknowledge it. It is in the user’s interests 
to take PrEP daily to maximise adherence, and removing the choice is a proportionate denial of 
autonomy as it still allows access. 
 
It may be that in some, albeit very rare, cases event-based usage is the best option for a potential 
user. For example, if an individual is generally low risk, though occasionally visits a bathhouse31 
and engages in risky sexual practices. There would be no need for this individual to take PrEP 
daily, and appropriate dosing before and after these trips to bathhouses would afford him strong 
protection against HIV infection. In such circumstances, it would be appropriate to allow 
healthcare staff to permit access to PrEP for event-based usage accompanied by appropriate 
guidance. For such potential users, it is better to allow access to event-based PrEP than for them 
to receive no PrEP at all. The requirement of necessity (Childress et al., 2002) is removed 
(meaning the necessity for daily PrEP as the only option), and beneficence is best met by making 
an exception. However, this is not a common occurrence, and daily PrEP ought to be imposed as 
the standard. Interestingly, the current PIT does permit potential users to choose a routine. This, 
I hold, is unethical and should not continue at the close of the trial. 
 
 
31 Venues where men can meet other men for casual, sometimes anonymous, sexual encounters. They are 




Future of PrEP administration 
 
Ethical issues I have just discussed pertain to PrEP taken either daily, on the days required by the 
Ts and Ss approach, or as an event-based precaution. All three options require the user to 
regularly remember to take the drug, and thus may result in nonadherence as highlighted. If other 
options for administering the drug were available, such as those currently being developed, some 
of these issues may become irrelevant, or at least less relevant. 
 
Of particular interest is LAI-PrEP, and clinical trials are currently taking place (Kaltwasser, 2018). 
The injectable, it has been suggested, would be taken every other month, in the hope that six 
doses each year will be easier for users to adhere to than daily/occasional pills. 
 
There are many benefits of the introduction of LAI-PrEP. Not only would it simplify adherence, 
but by administering the injection in a clinic healthcare teams would be able to maintain a record 
of a user’s adherence32. Regular clinic appointments to obtain daily PrEP do enable healthcare 
teams to test users for STIs, but there is no feasible method beyond self-reporting to ascertain 
adherence33. 
 
One potential issue is whether a user would fail to attend regular appointments for his next dose. 
This is possible, though unlikely to be common as no issues have been observed in users attending 
 
32 This assumes that LAI-PrEP would have to be administered by a healthcare professional rather than the 
user. It is possible that it may be self-administered eventually, but this would not likely be the case in the 
near future. 
33 Tests to check the level of the drug in the user’s blood are an option, but they would only show whether 
that user has been taking the drug recently. This, therefore, cannot be considered a reliable measure of 




quarterly clinic appointments to collect daily PrEP. Even though LAI-PrEP would require slightly 
more frequent visits – every other month rather than quarterly – this is not a significant enough 
increase to lead one to expect many users to struggle. 
 
LAI-PrEP would almost entirely remove the issue of nonadherence. The only related issue 
remaining is discontinuation. However, discontinuation would be far less likely to arise when a 
user is receiving LAI-PrEP than if taking PrEP in pill form as there would not be the potential for a 
gradual reduction in adherence leading to discontinuation. For someone receiving LAI-PrEP to 
discontinue would require either an active decision to do so, or serious difficulties in attending 
an appointment every other month34. 
 
The potential for LAI-PrEP raises the question, given my earlier assertion that daily PrEP ought to 
be imposed as the standard due to it having the lowest chance of resulting in nonadherence, of 
whether LAI-PrEP ought to be the standard if introduced. Nonadherence to LAI-PrEP is, as 
explained, not possible in the standard understanding of nonadherence. As such, I hold that if 
LAI-PrEP were introduced in clinical practice, it ought to become the default dosing option for the 
same reasons daily dosing ought to be the default now. Whilst the lack of choice would still insult 
the user’s autonomy, it would do so less overall. This is because there would be no need for a 
fixed time to take PrEP to be agreed with users, no need for daily SMS reminders35, and no need 
for more invasive means of monitoring adherence. Therefore, the introduction of LAI-PrEP will 
both improve adherence and allow greater respect for the autonomy of PrEP users overall. 
 
 
34 As LAI-PrEP would cover an individual for two months, it is not possible for users to discontinue between 
clinic visits as with oral PrEP. 




It is worth mentioning an alternative long-acting PrEP currently being developed in the form of a 
subdermal implant (Intarcia, 2016). Research into a PrEP implant is not as far along as LAI-PrEP 
but the technology may become available in the future. If available, the implantable PrEP would, 
it is hoped, last up to 12 months. A study has suggested that MSM may prefer a non-visible 
implant to LAI-PrEP in part because of protection duration; needing to attend a clinic less 
frequently is appealing (Greene et al., 2017). However, visiting a GUM clinic less frequently means 
less frequent STI testing. Improved ease of adherence in the case of a PrEP implant, then, could 
worsen the impact of risk compensation as STIs would be discovered and treated later than they 
would be with quarterly clinic visits. It is less clear that implantable PrEP ought to be the default 
means of dosing if available; LAI-PrEP may be better as it removes the adherence demands of 
daily PrEP from the user but still necessitates regular clinic visits to monitor health. Nonetheless, 
subdermal PrEP implants are far from ready, so the question as to whether it ought to be the 




Data concerning adherence to PrEP, PEP, and the BCP all point to PrEP nonadherence being a 
realistic prospect. It is not clear how prevalent it will be, but it will likely happen to some users. 
There is an issue of harm being caused in providing the drug if nonadherence reaches the point 
of discontinuation, particularly if coupled with risk compensation. 
 
The risk of nonadherence reaching the point of discontinuation in users is not alone great enough 
to make widespread availability of the drug necessarily unethical. However, the potential for 




then can the risk of undue harm to users be all but removed. Various methods may be feasible, 
such as mHealth approaches in the form of SMS alerts and/or greater efforts to monitor users 
and identify those struggling with adherence early. 
 
These issues and resolutions relate primarily to PrEP taken as a daily pill. This is the best method 
in terms of promoting adherence which ought to be the default, with other routines considered 
only in exceptional circumstances. 
 
Things may change with the introduction of LAI-PrEP, though this is not likely to be a reality for 
several years. Until then, the best way to promote adherence and avoid potential harm to users 
is to consider daily dosing the default, and to support users in establishing routine. If and when 
LAI-PrEP is introduced, provided no further ethical issues arise which could compromise it, it 
should become the default method of administering the drug as this will remove the possibility 







































In this chapter I consider how risk compensation36 – PrEP users feeling protected from HIV and 
engaging in riskier sexual practices – may affect how ethically defensible provision is. Whilst PrEP 
is prescribed as an additional precaution to be used concurrently with condoms, users may not 
sufficiently understand and/or follow this instruction. One study has even shown risk 
compensation to be an expected phenomenon in serodiscordant MSM couples (Brooks et al., 
2012). This has raised concerns that PrEP is enabling, perhaps even encouraging, risky sexual 
behaviour, with Duran raising the question, ‘For men who engage in unsafe sex with other men, 
is this [PrEP] just an excuse to continue to be irresponsible?’ (Duran, 2016).  
 
Following an initial explanation of the theory of risk compensation, I ask whether it is likely 
individual-level risk compensation in PrEP users would result from widespread provision of the 
drug. This requires separate consideration of three sub-groups of potential PrEP users, the 
classification of which is outlined. I look to previous trials of PrEP and any evidence of risk 
compensation they provide, as well as qualitative studies which explore the phenomenon. I then 
consider community-level37 risk compensation, which has a lesser evidence base but is just as 
important. To estimate the likelihood of risk compensation at the community-level, I look at the 
impact of the introduction of HAART on sexual behaviour in MSM. 
 
After assessing the likelihood of both individual- and community-level risk compensation, I discuss 
whether the existence of these phenomena is an obstacle to the ethical provision of PrEP. 
Acknowledging the value and role of justice, I consider the indirect impact risk compensation 
might have on the wider population, as well as questioning whether the effect it may have on the 
 
36 Also known as ‘risk homeostasis’ or ‘behavioural disinhibition’. 




individual – be that a PrEP user or an individual who is affected by community-level risk 
compensation – can be reconciled with the principles of beneficence and nonmaleficence. 
 
When discussing the benefits and harms of PrEP, I consider only health-related effects. Sexual 
liberation is often raised as a benefit of PrEP which may be considered as countering the harms 
of risk compensation. I do not, however, take this into consideration for the reasons outlined in 
Chapter III. Where PrEP is available it is provided as an additional precaution, to be used alongside 
condoms. It is not intended as a replacement for condoms or to encourage CAS so I focus only on 
health-related issues and consider reduced condom use a negative consequence. If one were to 
consider sexual liberation as an important benefit, my conclusions may not hold. 
 
I will begin by providing a more detailed explanation of what risk compensation is and what it 
means in the context of PrEP. 
 
What is risk compensation? 
 
Risk compensation describes the phenomenon whereby real or perceived protection from a risk 
provided by an intervention results in riskier behaviour (Cassell et al., 2006). The theory of risk 
compensation rests on the idea that individuals have target levels of risk which they aim not to 
exceed. Consequently, when an intervention reduces the risk of X, there is room for an individual 
to increase the risk in other ways without exceeding their target level of risk (Wilde, 1982). Take, 
for example, road safety. Seatbelts were introduced to reduce the risk of harm in road traffic 




avoid collisions, resulting in riskier driving practices (Richens et al., 2000). Another parallel is 
found in the case of sunscreen use and an increase in sun exposure (Autier et al., 1998). 
 
With PrEP, risk compensation means users recognising the protection from HIV the drug provides 
and engaging in riskier sexual behaviours. In addition to decreased condom usage, there may be 
an increase in the number of partners, shorter periods of time between partners, less concern 
with partner characteristics, and a decrease in serosorting,38 all because users feel at less risk of 
HIV infection (Nguyen et al., 2018). This is supported by a perception that STIs are easily cured 
(National LGBTQ Task Force Action Fund), suggesting the main reason for using condoms would 
be HIV prevention. These riskier behaviours put users at an increased risk of STIs and potentially 
HIV if users were nonadherent (see Chapter IV). 
 
This change in sexual behaviour may be intentional, whereby an individual acknowledges the 
effect of PrEP and decides riskier sexual practices are not as worrying as previously, or passive, 
such as an individual who initially consistently uses condoms in addition to PrEP but gradually 
does so less, perhaps for the sake of convenience, justified by a background belief that he is 
protected. Risk compensation theory would be directly applicable to the potential increased risk 
of HIV from PrEP users engaging in riskier sexual practices. There are, however, other effects to 
consider, such as the increased risk of STIs individuals put themselves at. Whilst other risk 
behaviours which may arise in PrEP users are concerning, the primary focus of this chapter is the 
increase in CAS.39  
 
38 The practice of deciding against sexual activity with HIV+ individuals. 
39 An increase in CAS is the most commonly raised issue concerning risk compensation with PrEP and is that 
which can be most clearly linked to an increase in STIs. Other high-risk behaviours would only significantly 




Sexual risk compensation among MSM may also arise due to greater HAART availability, or the 
knowledge that HIV+ individuals with an undetectable viral load cannot pass on the virus40 
(Rodger et al., 2019). These contributing factors are touched on, though PrEP remains the primary 
focus. It is unlikely these other contributors are acting alongside perceived protection from PrEP 
as HAART has been available for many years, and it is likely to be difficult for many men to 
knowingly have CAS with an HIV+ individual even if they know they cannot pass on the virus, as 
the stigma associated with HIV is still strong. 
 
Risk compensation is potentially the most problematic issue surrounding PrEP provision. This is 
primarily due to the extent of disagreement over the reality of the phenomenon. Whilst some 
studies have found risk compensation (Newcomb et al., 2018), others argue PrEP is more likely to 
result in safer sexual practices (Grant et al., 2010). The latter is based on the requirement of most 
systems of provision requiring frequent (usually quarterly) visits to a GUM clinic, and the 
suggestion that regular reassurance of the need for condom use in addition to PrEP will eventually 
have a positive impact in influencing sexual risk behaviour. What intuitively feels more realistic is 
that risk compensation associated with PrEP will be somewhere in between; some users will begin 
to take more risks with their sexual health, some will begin to practise safer sex, and others will 
continue acting just as they did before they commenced PrEP. 
 
Continuing as before does not necessarily mean the concurrent use of PrEP and condoms. The 
main target population in the PIT is those who frequently engage in CAS (PrEP Impact Trial, 
2017b). For these individuals, risk compensation is less relevant. They may begin to be less 
cautious of who they engage in sexual activity with, meaning not asking potential sexual partners 
 




about their sexual health, but if these individuals did not use condoms before commencing PrEP 
then it is not possible for there to be a reduction in their condom usage. 
 
I will now move to consider the likelihood that PrEP would result in risk compensation and, if it 
would, the extent to which it would. 
 
Does/would PrEP cause risk compensation? 
 
Risk compensation does not affect everyone in the same way. Some will be unaffected. Members 
of the MSM community are not equally committed to practising safe sex, so there is a range of 
attitudes to condom use. It is prudent to distinguish between sub-groups of MSM to discuss risk 
compensation. I discuss three groups: (1) those who already engage in CAS either always or 
frequently; (2) those who mostly use condoms, but occasionally engage in CAS; and (3) those who 
consistently use condoms.41 These groups are considered, and thus referred to as, high-risk 
individuals (HRIs), medium-risk individuals (MRIs), and low-risk individuals (LRIs) respectively. 
Classifying them as such is not based on any strictly medical grounds, but an intuitively fair 
assessment of the risk of HIV infection in those who fit these groupings how they may be 
differently affected by risk compensation.42 
 
 
41 It is worth noting that those who fit one of these categories but are in a monogamous relationship with 
a partner who is HIV- are not being discussed. Such individuals are at a very low risk of HIV infection, in that 
a risk of infection through sexual activity would exist only as a result of infidelity. Those in open relationships 
(broadly defined), however, are still at risk and are, therefore, included in discussion. 
42 This assumes there are no non-sexual HIV risk factors in their lives. If a man were also an intravenous 
drug user there would be additional risk, but it is fair to assume that the majority of MSM are not 




HRIs are the primary target audience for PrEP. Those consistently engaging in CAS are at a very 
high risk of HIV infection, with this risk increasing with the frequency both of instances of CAS and 
of new sexual partners (Wilton, 2012). The potential for risk compensation among this group is 
limited; as they already engage in regular CAS there is little, if any, room for a higher percentage 
of their sexual encounters to involve CAS. Indeed, one individual who would fall under this 
classification stated: ‘the notion of wearing a condom is almost as oppressing as abstinence’ 
(Alvarenga, 2017). It is, however, possible for them to engage in more CAS in terms of frequency. 
It is also possible for them to grow less concerned with serosorting. If the HIV+ individuals HRIs 
have CAS with are virally suppressed this is not problematic as HIV cannot be passed on in such a 
scenario, but those who are newly diagnosed and not virally suppressed do present a risk to HRIs 
even if adherence to PrEP is perfect.43 
 
Risk compensation findings from PrEP trials are mostly applicable to HRIs as this group is the 
target population. These trials almost unanimously deny the occurrence of risk compensation in 
PrEP users44 (Grant et al., 2014; Molina et al., 2015; McCormack et al., 2016; Grant et al., 2010). 
The IPERGAY (Molina et al., 2015) and the iPrEx (Grant et al., 2010) studies both observed no 
change to sexual practices among participants, with iPrEx going further in finding both an increase 
in condom use and decrease in the number of sexual partners. However, both were placebo-
controlled trials. It is unrealistic to expect useful data on risk compensation in a placebo-
controlled trial as participants do not know whether they are receiving the drug; without 
knowledge that one is on PrEP for certain, the psychological process behind risk compensation 
cannot take place. Safer sexual practices in this trial may have resulted from greater awareness 
of HIV risk; participation in the trial would expose individuals to more information about the virus 
 
43 With perfect adherence there would be minimal risk, but still some as PrEP is not 100% efficacious. 




and its transmission. For this reason, we can dismiss these findings as conclusive on the point of 
risk compensation. 
 
The PROUD (McCormack et al., 2016) study, however, and an extension to iPrEx (Grant et al., 
2014), were both open-label trials. Participants in both the immediate and deferred groups of the 
PROUD study had balanced baseline characteristics, and findings suggested there was no change 
in sexual behaviour. PROUD claims to ‘refute concerns that the effectiveness of PrEP would be 
compromised in a real-world setting’ (McCormack et al., 2016) by noting no significant difference 
in STIs between groups. However, this study was just 84 weeks long. Risk compensation is not an 
immediate response. The added sense of protection is something that develops over time, 
leading to a gradual decline in condom use. A long-term study would be required to properly 
examine the likelihood of risk compensation resulting from PrEP provision. The iPrEx extension is 
similarly problematic, having lasted just 72 weeks (Grant et al., 2014).  
 
It is important to qualify findings concerning risk compensation in early PrEP trials with the fact 
participants are highly motivated individuals in the MSM community whose experiences may be 
different to those of potential future PrEP users. As noted by Grace and colleagues, these 
individuals are ‘more likely to experience and/or report an optimistic or positive outlook on PrEP’ 
(Grace et al., 2018). Further, when risk compensation is measured primarily through self-
reporting,45 social desirability bias may distort findings (Treibich and Lepine, 2018); those 
engaging in riskier sexual activity as a result of PrEP may lie about condom use as they do not 
want to admit to something perceived as socially undesirable (see Chapter VI). 
 
45 Incidences of STIs are also considered to assess risk compensation, but such a measure is unreliable 




More recently, several studies have looked at risk compensation among PrEP users (Nguyen et 
al., 2018; Beymer et al., 2018). They are likely to be more reliable than PrEP trials as not only do 
they assess risk compensation through STI instances rather than self-reporting, but also the 
participants were not part of a clinical trial. 
 
These studies do show, based on a comparison of STI instances in the 12 months before and after 
PrEP initiation, that risk compensation does happen. Nguyen and colleagues found STI instances 
increased from 52 to 91 (n=109), in addition to two cases of HIV seroconversion (Nguyen et al., 
2018). Increases were evenly spread across STIs, with the only decrease found in urethral 
gonorrhoea. Beymer and colleagues, however, found very different results between STIs based 
on a larger cohort (n=275) (Beymer et al., 2018). Prevalence of many STIs remained the same, 
though rectal chlamydia instances increased by 29% and syphilis by 164%. The increase in syphilis 
may be explained by the possibility of transmission despite condom use, or the overall upward 
trend in syphilis at that clinic. Rectal chlamydia, however, did not see an overall increase in 
instances at that clinic, so the increase among PrEP users may more feasibly be attributed to risk 
compensation. It makes sense that the increase would be in a rectal rather than oral STI as the 
(dis)use of protection for oral sex is unlikely to be affected by PrEP. With both studies examining 
risk compensation only over a 12-month period it is possible risk compensation would not yet be 
notably observable. There remains, then, a need for a study which measures long-term trends. 
 
The participants in most previous PrEP trials and studies have been HRIs. Therefore, if one were 
to accept the findings of these trials on risk compensation there is no information on risk 
compensation in MRIs or LRIs. Whilst HRIs are the target audience for PrEP, it is naïve to think 
they will be the only ones accessing the drug (see Chapter VI). It is important to explore the 




MRIs are those who mostly use condoms, but occasionally engage in CAS. This group is perhaps 
most susceptible to risk compensation in theory, as the fact they already engage in CAS from time 
to time suggests it is something they enjoy but try to avoid out of fear of the potential 
consequences, perhaps when the sexual history and/or HIV status of their sexual partner(s) is 
unknown to them. When you add to this scenario the protection PrEP affords, it is reasonable to 
assume some MRIs would respond with a greater tendency to engage in CAS. Fear of HIV might 
gradually erode due to their knowledge of the efficacy of PrEP (with them likely equating efficacy 
with effectiveness) and they may more frequently engage in CAS, with some possibly reaching 
the point of becoming classed as HRIs. 
 
In Canada in 2016, risk compensation emerged as a theme in a study of the impact of PrEP on the 
social and sexual lives of MSM (Grace et al., 2018). Several interviewees described PrEP as 
liberating them from the need to use condoms, with some drawing an analogy with the BCP 
liberating women sexually. One, talking of his experience as a PrEP user, said: ‘Now that I can 
have bareback sex [CAS] again, it’s just fantastic. Sex has been liberating again thanks to PrEP’  
(Grace et al., 2018). This particular interviewee spoke of frequent visits to bathhouses and an 
active sex life. Combined with him saying he can now have bareback sex again, this suggests he 
is rightly classed as MRI. This study also noted a key overarching assumption in the social and 
sexual networks of the men interviewed was that PrEP and CAS are frequently equated. 
 
We certainly cannot take the experience of one man and the general views of the sample 
interviewed in this single study as representative of the entire MRI population, but the fact these 
examples exist is evidence that risk compensation will take place among MRIs to some extent. 
Further, a recent systematic review and meta-analysis of the relationship between PrEP and risk 




condoms (Traeger et al., 2018), and these individuals would fall under the classification of MRI. 
This study also found the association between PrEP use and STI diagnoses to be stronger in later 
studies, suggesting increased faith in the drug has also contributed to an increase in risk 
compensation over time (Traeger et al., 2018). It is hard to say how widespread it would be, but 
it is very likely to happen to some degree if PrEP were made widely available, and that needs to 
be accounted for in any decision to roll out the drug. 
 
I will now consider risk compensation among LRIs. The fact LRIs consistently use condoms may be 
for any reason but is most likely a desire to avoid STIs and, most importantly, HIV. LRIs have 
absorbed the long-term message that condoms are the best way to practise safe sex and are 
taking it seriously. It is unlikely they would knowingly have even protected sexual intercourse with 
an HIV+ individual out of fear of infection. You may think risk compensation is very unlikely among 
this group. Indeed, under PIT guidelines, if they were being honest in a clinical risk assessment, 
LRIs would never have access to PrEP through official channels.46 However, there is a possibility 
that LRIs would lie to access PrEP or purchase it online; if these individuals are so fearful of 
becoming infected with HIV, it does not seem unreasonable to assume some would lie about their 
sexual behaviour to access PrEP if the drug were available. One could also argue that even if PrEP 
were not made freely available it is accessible online. This is true, but instances of LRIs purchasing 
the drug online would likely be rare without the national promotion and awareness that would 








One PrEP user who perfectly fits the description of an LRI is Joel Alcaraz, who has written about 
his experience online (Alcaraz, 2015). Alcaraz described his thoughts concerning sexual contact 
with HIV+ partners: ‘My fear was so deep I could barely kiss them without thinking about the 
terrorist virus within their bodies’ (Alcaraz, 2015). Given how severe Alcaraz’s fear of HIV was, 
even PrEP, it would be reasonable to assume, would have been insufficient to prompt risk 
compensation; someone like Alcaraz would likely want PrEP as an added precaution only, with no 
view to replacing condoms. However, Alcaraz wrote of how since starting to take PrEP he has 
become more open to CAS. Further, he has since been diagnosed with STIs, which he claims never 
happened prior to him starting on PrEP. 
 
A similar story, both more recent and from the UK, is that of Adam MacLean (Ryan, 2018). Having 
previously used condoms 100% of the time for over a decade, MacLean initiated PrEP following 
CAS during a drunken encounter. He confesses both his condom use and fear of HIV began to 
decline when on PrEP. Whilst we do not know if MacLean began to contract STIs as a result, what 
is certain is his risk compensation would have put him at a greater risk of doing so. Rather than 
completing a course of PEP after the incidence of CAS and continuing to use condoms, MacLean 
made a decision which later put him at greater risk of STIs. 
 
The stories of both Alcaraz and MacLean highlight the potential for risk compensation among 
LRIs. This is something seldom acknowledged due to the fact LRIs are not the target population. 
However, LRIs may access PrEP. 
 
Risk compensation among individuals taking PrEP is something to be expected if the drug were 




outweigh the benefits of PrEP, however, is up for debate, particularly among the different risk-
based sub-groups. Whilst it is likely that widespread availability of PrEP would result in riskier 
sexual practices among some users, this does not necessarily mean PrEP should not be made 
available, as it is possible the benefits outweigh the harms. Equally, additional efforts could be 
made to prevent risk compensation. I consider the extent to which risk compensation should 
affect decisions surrounding the availability of PrEP later in this chapter. First, though, I assess the 
likelihood of risk compensation taking place at a community-level. 
 
Community-level risk compensation 
 
Risk compensation is, first and foremost, concerned with changes to the risk activity of the 
individual the intervention is aimed at (i.e. PrEP users). However, an interesting study in Australia 
raises the issue of community-level risk compensation, or ‘prevention optimism’47 (Holt et al., 
2018). Prevention optimism in the context of PrEP describes the situation whereby widespread 
availability of PrEP results in increased risky sexual behaviour by those not on the drug themselves 
due to a belief that enough others will be on PrEP to afford them protection – almost like herd 
immunity. It is important we consider the effect PrEP may have on ‘community norms and 
practices’ (Holt and Murphy, 2017) as well as PrEP users themselves. 
 
Following the introduction of PrEP, condom use by MSM in San Francisco, USA, decreased (Chen 
et al., 2016). This included individuals not themselves using PrEP, which researchers suggested 
was a result of the assumption that other men would be. This demonstrates a potential for 
 
47 The term ‘risk compensation’ will be used solely to refer to individual-level risk compensation from now 




prevention optimism following the introduction of PrEP; not only PrEP users engaged in more 
CAS, but the wider community too. 
 
Prevention optimism has also resulted from the availability of HAART for the treatment of HIV+ 
individuals. Knowledge that HAART enables HIV+ individuals to live normal lives, in contrast to the 
devastating prognosis that once followed a diagnosis, appears to reduce fear of the virus. 
 
One study in Amsterdam found MSM were generally realistic about the continued need for 
condoms following the introduction of HAART and acknowledged that the treatment does not 
affect one’s chances of infection (Stolte et al., 2004). However, those who perceived a lesser 
threat of HIV/AIDS given the availability of HAART were more likely to engage in more CAS. These 
results are reinforced by a meta-analysis carried out to assess the relationship between HAART 
and sexual risk behaviour (Crepaz et al., 2004). Previous studies have disagreed with this 
conclusion (Elford et al., 2002; Huebner and Gerend, 2001). However, both were cross-sectional 
studies. The Amsterdam study (Stolte et al., 2004) was longitudinal, so is more reliable in 
assessing behavioural changes like prevention optimism. 
 
There appears to be a risk of prevention optimism with PrEP. However, a valid point is made by 
Stolte and colleagues (Stolte et al., 2004) that their findings should not be generalised as 
applicable to the whole MSM population. Whilst their study was concerned with the impact of 
HAART availability, this message is just as relevant to the case of PrEP. Prevention optimism would 
not necessarily be a widespread phenomenon if PrEP were made available, and certain sub-
groups of the population may not respond in such a way at all. In considering the ethics of PrEP 




remaining realistic about how widespread it would be as it would be difficult to accurately 
ascertain this data. 
 
Now that I have presented a case for the likelihood of risk compensation at both the individual- 
and community-levels, I explore the extent to which this affects the ethics of PrEP provision. 
 
Ethics and risk compensation 
 
The risk compensation debate surrounding PrEP concerns the question of whether a reduced risk 
of HIV is a good enough reason to put an individual at a potential increased risk of STIs. The 
intention of PrEP – reducing users’ chances of HIV infection and, as a result, reducing the spread 
of the virus – is good. However, equally, an increased risk of STIs is problematic. If the benefit of 
reducing the risk of HIV outweighs the harm of increased susceptibility to STIs, PrEP may be 
deemed ethically sound. Here lies the ethical conflict, chiefly as a matter of autonomy versus 
nonmaleficence, though questions of beneficence arise in considering HRIS as well as justice from 
a population-level perspective. The move to deny access to PrEP may, I suggest, be justified on 
such grounds. 
 
PrEP for HRIs is the least ethically problematic. We know risk compensation does not affect these 
individuals as they already consistently engage in CAS. PrEP appears to afford HRIs the benefit of 
a reduced risk of HIV without the harm of an increased risk of STIs. Therefore, at an individual-
level, the provision of PrEP to HRIs is ethically permissible and may even be considered a 
beneficence-based imperative. Objections to PrEP for HRIs based on risk compensation are only 




Individual-level risk compensation may, however, be a valid ethical objection to the provision of 
PrEP to MRIs and/or LRIs. 
 
If PrEP were available to MRIs, STI diagnoses in this group would likely rise. This group is likely to 
be affected most by risk compensation as they are already open to CAS, and their commitment 
to condom use may gradually erode. 
 
MRIs would certainly derive some benefit from PrEP in terms of a reduction in HIV diagnoses. 
Before PrEP, this group is usually protected by condoms from both HIV and STIs, though not 
always. For those instances where condoms are not used, the risk of HIV infection would be 
almost entirely removed if they were taking PrEP (assuming good adherence). Likelihood of HIV 
infection for MRIs is, then, going from moderate to negligible. This drop is not significant, though 
given the incurable nature of HIV an intervention which even slightly reduces the chances of 
infection for MRIs is, at first glance, beneficent; indeed, it is for this reason that I have noted the 
justification of PrEP provision for HRIs above. However, members of this group could be 
significantly affected by risk compensation. 
 
An increase in STIs among MRIs would constitute harm. Even if STIs are not perceived as serious 
and it is only HIV they hope to avoid, an intervention resulting in greater susceptibility to STIs fails 
to fulfil the principle of nonmaleficence where a suitably greater benefit does not exist. Acting to 
prevent PrEP access is justified on the basis of nonmalefience, and does not inappropriately 
infringe on the individual’s autonomy as not perceiving STIs as serious can be taken as a defect in 
decision-making; the rise of antibiotic resistance in STIs is not common knowledge, so it is 




risks associated with STIs. The fact anyone given PrEP is told to also use condoms is not a strong 
enough counterargument as even if an MRI says he sufficiently understands the need for 
condoms in addition to PrEP at a GUM clinic, this does not mean that he will take this message 
on board in practice; such an individual may only fit classification (d) in terms of intentionality, 
thus deeming him insufficiently autonomous. This is partially because risk compensation is not 
necessarily an active decision by the individual. The feeling of protection from HIV grows almost 
subconsciously, resulting in individuals having more CAS despite originally intending to take PrEP 
as an additional precaution rather than a replacement. It may also be that an individual simply 
lies in saying he accepts the need for concurrent condom use when in fact he has no intention of 
doing so, though this is unlikely to be the case with a significant proportion of MRIs. 
 
As MRIs are afforded only a small additional amount of protection from HIV when taking PrEP, 
there would need to be almost no adverse effects for this intervention to be ethically sound. The 
benefit of PrEP for MRIs is small enough that the increased risk of STIs outweighs it. The balance 
of good to bad outcomes at the individual-level when PrEP is provided for MRIs is such that it 
cannot be considered an ethically permissible intervention overall as it violates the principle of 
nonmaleficence. Of course, it would be excessive to declare all MRIs who take PrEP would 
succumb to risk compensation. Some would continue to use condoms frequently, which would 
mean PrEP would have an overall positive impact on their sexual health. However, until it can be 
demonstrated that a small enough proportion of MRIs would engage in CAS when on PrEP to 
result in a positive average outcome for individuals in this population, the medical harms appear 
to outweigh the medical benefits.48 It may be argued it is for individuals to decide whether they 
prefer the risk of other STIs to HIV, but this is not something for medical actors to enable when 
 
48 Given the low risk of HIV infection MRIs are at prior to commencing PrEP, the benefits (a reduced risk of 





condoms are a cheaper and equally efficacious option, and the fact that alternatives are available 
makes for a lesser insult to the individual’s autonomy (see Chapter III). Further, it is a 
proportionate infringement on autonomy which satisfies the conditions previously outlined 
(Hermerén, 2012); the end goal of preventing the spread of infections is important, denying PrEP 
in this situation might feasibly achieve this, no less controversial means is available, and denying 
access to PrEP is not excessive. 
 
The particularly ethically problematic group in terms of individual-level risk compensation is LRIs. 
There is a reasonable risk these individuals will begin to engage in CAS as a result of being on 
PrEP, putting them at significantly greater risk than they previously were; from <1% chance of 
becoming infected with an STI as a result of anal intercourse to having no barrier to infection. 
There is also potential for them ending up at greater risk of HIV infection if they suffer 
nonadherence, meaning that second to the significant harm of an increased risk of STIs, such 
individuals do not experience the intended medical benefit of PrEP. 
 
LRIs have good condom use, meaning they are at a very low risk of HIV infection to begin with. 
There is no medical need for this population group to use PrEP. Condoms are as efficacious as 
PrEP in preventing HIV (in addition to preventing against other STIs) and LRIs are likely to do well 
with event-based usage to ensure effectiveness. To provide them with an unnecessary drug, 
which they must commit to taking daily, is, as a cumbersome routine alone, a burden. Adherence 
to daily drugs can be stressful, particularly when individuals miss doses (see Chapter IV), and LRIs 
would be taking on this potential stress without deriving any clear medical benefit.49 This, in 
 
49 It is worth noting, even though I am not concerned with the role of sexual liberation, that LRIs would not 
even benefit from sexual liberation in the way MRIs might. Given the general attitudes of LRIs towards safe 




addition to a potential increased risk of HIV infection and a significantly higher risk of other STIs, 
makes for an ethically dubious intervention. 
 
There is no ethical basis for providing LRIs with PrEP in terms of risk to benefit ratio; indeed, the 
opposite is true. The harm risk compensation presents to LRIs is greater than any potential 
medical benefit. Allowing LRIs access to PrEP is, therefore, ethically irresponsible from a solely 
medical perspective. 
 
I have assessed the ethical permissibility of providing PrEP to HRIs, MRIs, and LRIs on an individual-
level, though there are also population-level implications. I am not referring to prevention 
optimism as that is a community- rather than population-level issue.50 When individuals are 
provided with PrEP and risk compensation ensues, the wider population sees a small increased 
risk of STI infection without having caused it (and perhaps an increased risk of HIV infection too 
if PrEP users are not fully adherent, though this would likely be statistically insignificant if it arose 
at all). 
 
If PrEP users become more susceptible to STIs, they would begin to spread more quickly. This 
would begin to affect individuals outside the MSM community; MSMW who are either on PrEP 
themselves or have CAS with PrEP users would become a means for STIs to move from the MSM 
community to heterosexual and bisexual women initially, and, later, heterosexual men. The 
extent to which this would arise is difficult to judge. There are several “what ifs” before this point 
 
50 Prevention optimism is discussed in terms of the effect of PrEP on the MSM and, to a lesser extent, men 
who have sex with men and women (MSMW), community rather than the wider population. It is possible, 





is reached. However, it is not unrealistic to suggest it could eventually happen. PrEP provision 
would, indirectly, put members of the wider population at an increased risk of STIs when they are 
not even aware of it. When the wider population is not sufficiently aware of their increased risk 
of an STI, their ability to make risk decisions is removed; they are unable to sufficiently exercise 
autonomy as they would not fulfil the criteria of sufficient understanding. Few are fully aware of 
the level of risk they are taking when engaging in unprotected sex, and knowledge of this small 
increase in risk may not affect decisions members of the wider population would make, but it is 
still contrary to the principle of nonmaleficence at a population-level for individuals to be put at 
an increased level of risk when unaware, especially when it affords them no benefit.51 Whilst a 
key element of population health interventions – limiting individual autonomy in the interests of 
the health of the population – it does require a significant enough benefit to the overall health of 
the population. PrEP, as demonstrated, does not present a sufficiently strong health benefit as to 
permit this stealth increase in the risk of STIs in the wider population, meaning the autonomy of 
the individual can justifiably be side-lined in pursuit of nonmaleficence at a population-level. 
 
This population-level risk is only applicable when discussing the provision of PrEP to MRIs and 
LRIs. As HRIs are not affected by risk compensation, they would not be contributing to a greater 
spread of STIs than they already are. MRIs and LRIs would. We cannot be sure how prevalent this 
would be. It may be that the benefits gained by the individuals on PrEP are significantly greater 
than the sum of harm done to the whole population, making a net benefit gain. However, as MRIs 
and LRIs are not afforded an individual benefit overall, and HRIs are not affected by risk 
compensation, this seems unlikely. 
 
51 It is hoped that the provision of PrEP will reduce the spread of HIV which could, eventually, result in 
everyone’s risk of infection being reduced. However, this is an indirect result and is not a significant benefit 




Ethics and prevention optimism 
 
The debate over prevention optimism concerns all groups – HRIs, MRIs, and LRIs. Prevention 
optimism seems a likely result of PrEP provision – though the likely extent of the phenomenon is 
unknown – which is ethically problematic. It sees harm coming to individuals without them 
benefitting from PrEP. Whilst it is still the individual’s actions directly putting them at risk, the 
provision of PrEP causes the behavioural change responsible. If prevention optimism becomes 
prevalent, it would constitute a public health concern that may outweigh the benefits of PrEP to 
users. Victims of prevention optimism may be deemed as having a defect in decision-making in 
assuming herd immunity – thereby missing a single important fact which can undermine 
autonomy (see Chapter III) – which suggests some action in meeting the demands of 
nonmaleficence is justified. Though in the case of prevention optimism, it is worth noting that 
such action would be directed at another; the PrEP user is the subject of the action rather than 
those who experience prevention optimism, introducing an element of justice as overriding 
autonomy as the individual would be expected to forego PrEP – which he wants – for the benefit 
of the wider population. 
 
Prevention optimism would prove a bigger issue for HRIs than anyone else if it resulted in PrEP 
being made unavailable, as this group stands to gain the most from provision of the drug. HRIs 
benefit most from PrEP and are least affected by risk compensation. Therefore, PrEP is an 
intervention which is justified for this group on an individual-level. However, the actions of others 





If PrEP provision were to result in prevention optimism, it would pose a risk to public health. It 
then becomes a question of the autonomy of the individual versus the application of 
nonmaleficence to the wider public. Let us assume that PrEP is only available to HRIs.52 There is a 
significant benefit to the health of those individuals, meaning a significant overall benefit to the 
health of that group. However, prevention optimism introduces a potential risk to the health of a 
much wider pool of individuals. It could affect those at practically zero risk of HIV infection by 
introducing this risk, as well as increasing the spread of STIs. This could be the case beyond 
population groups such as MSM, who are currently most affected by HIV. Heterosexuals could 
see a heightened risk of infection too. This could result from infections moving from the MSM 
community via MSMW; whilst this already can, and does, happen, it could happen more 
frequently if prevention optimism happened as MSMW who currently use condoms may stop 
doing so and thus increases the potential for carrying infections across. 
 
Antimicrobial resistance is also an issue with prevention optimism, and potentially more 
significantly so than with risk compensation. In 2015, there was an outbreak of ‘super-
gonorrhoea’53 in Leeds (Gallagher, 2015). More recently, in 2018, a heterosexual man presented 
with a highly resistant strain of gonorrhoea, resulting in a Public Health England (PHE) 
investigation (Schnirring, 2018). Whilst both situations were dealt with, the risk of drug-resistant 
infections is a cause for concern throughout healthcare (Viens and Littmann, 2015; Littmann and 
Viens, 2015), and sexual health is no exception. Prevention optimism, in increasing the spread of 
STIs, would contribute to this problem; it would cause more individuals to become infected 
before sexual health services become aware, causing a much more widespread, and thus 
expensive, problem to deal with. 
 
52 This is an unlikely reality (see Chapter VI) and is raised purely for the sake of discussion. 




As prevention optimism has the potential to cause significant problems at a population-level, it is 
unethical to permit widespread access to PrEP unless this risk can be either minimised or 
disproved. Decreasing the already low risk of HIV infection54 in a small group of individuals is not 
a significant enough justification for putting the wider population at greater risk of STIs. This is 
the case for the provision of PrEP to HRIs, MRIs, and LRIs; prevention optimism may be less 
widespread if PrEP were only available to HRIs as other people would be less inclined to assume 
enough people are taking the drug, but it would still take place and thus remains as an important 
consideration in the provision of PrEP.  
 
This debate would be very different if PrEP were the only barrier to HIV. If there was no other 
way to prevent against the virus (i.e. if condoms did not exist), it may be less clear that population-
level risks introduced by prevention optimism outweigh the protection PrEP affords users. 
However, the fact condoms exist and are freely available cements arguments against PrEP 
provision based on prevention optimism. We cannot reconcile increasing the risk of both HIV and 
STI infections throughout the population to lower the risk of HIV infection for a small group of 
individuals with the principles of nonmaleficence and justice, especially when those individuals 





54 Whilst HRIs are considered at high risk of HIV infection, their chances of infection are still low due to how 
difficult it is to spread HIV. Their risk is high relative to others. 
55 At first, it may appear as though the logical extension of this argument would suggest the BCP ought not 
to be available. There are several reasons why this analogy does not hold and the BCP can remain justified 






Risk compensation stands as a valid individual-level argument against the provision of PrEP for 
MRIs and LRIs, though not for HRIs, and both prevention optimism and the population-level 
impact of risk compensation provide ethical obstacles to the provision of PrEP for any MSM 
population group. This is the case assuming PrEP is rolled out with no efforts to counter the 
effects of risk compensation and prevention optimism, or with efforts that are weak and 
ineffective. Cassell and colleagues make a very good point on this front: 
 
‘The prospect of risk compensation should not deter us from pursuing promising 
methods of prevention or treatment, but it is imperative that we plan ahead to ensure 
that the benefits will significantly exceed any potentially offsetting limitations.’ (Cassell 
et al., 2006) 
 
Certainly, if appropriate additional measures were in place to prevent, or significantly minimise, 
risk compensation and prevention optimism it would become ethically permissible to provide 
PrEP. The problem is in finding measures that will achieve this. Making continued access to PrEP 
conditional on various forms of health counselling or other methods of changing the views of 
users towards CAS is one option. This would likely work for some users, but until it can be 
demonstrated as working for a significant majority it is not grounds for the ethical provision of 
PrEP. Further, it would do nothing to address prevention optimism. Since prevention optimism 
arises in those who are not on PrEP, there is no obvious way for these individuals to be targeted 
with any form of advice or warning. At the very least, efforts to monitor risk compensation in the 




Until approaches to reducing or eradicating risk compensation and prevention optimism are 
demonstrated to work, PrEP provision cannot be justified as it is irreconcilable with the principles 
of nonmaleficence and justice even if users are acting sufficiently autonomously. The only point 
at which risk compensation does not become a barrier to ethical PrEP provision is in the case of 
HRIs from a solely individual-level perspective. However, for this group, prevention optimism is 
still a potential issue, thus undermining the benefits gained until prevention optimism can be 
demonstrated to be minimal. 
 
My conclusions are based on several assumptions. These are necessary due to a lack of available 
evidence; there are insufficient data on changes to risk behaviour to suggest how widespread risk 
compensation and prevention optimism would be. It is important to note these assumptions are 
falsifiable, and if they are demonstrated to be inaccurate my conclusions would be undermined. 
What is needed are more empirical data so that any conclusions drawn are either supported or 
shown to be wrong, both normatively and practicably. However, in the absence of such data, the 
assumptions my conclusions depend on are reasonable and sufficiently justified. Here I invoke 
the precautionary principle and its focus on pre-damage rather than post-damage control (United 
Nations Educational, Scientific and Cultural Organization World Commission on the Ethics of 
Scientific Knowledge and Technology, 2005); it is preferable to wait until we have evidence that 
PrEP is not harmful rather than introducing it and risking a high prevalence of risk compensation, 
as to withdraw PrEP provision in the latter scenario would entail significant backlash from the 




































Having discussed the potential risks associated with PrEP use, particularly in relation to risk 
compensation in MRIs and LRIs, it is apparent that effective targeting of suitable users is 
important to minimise harm. The aim should be to ensure only HRIs have access to PrEP because 
they are the group which can ethically be provided with the drug (see Chapter V). However, this 
may not be a realistic prospect.  
 
I begin this chapter by outlining the target population of the PIT. This model is most likely to 
reflect the target audience clinical guidelines will stipulate if PrEP is to be made widely available 
following the conclusion of the trial. The user criteria are much the same throughout the UK, 
whether as part of a trial or not. 
 
The next section addresses the problem with self-reporting that has been touched on in previous 
chapters. Given the nature of the eligibility criteria used in the PIT, elements of that eligibility can 
only be assessed by self-reporting. The problem with self-reporting is that individuals who do not 
meet eligibility criteria can be assessed as meeting them due to dishonest or mistaken responses 
from prospective users, granting them access to a drug they ought not to have. I explore the long-
term issue of “clinic hopping”, whereby users present at clinics to obtain PEP for use as PrEP. 
 
I then outline ethical issues associated with self-reporting as a measure of PrEP eligibility and 
consider whether they are reconcilable to the point of making effective targeting of PrEP possible. 
The focus of this discussion is the principle of nonmaleficence and whether it can override 




harm.56 It also asks whether it is justifiable to prevent MRIs and LRIs accessing PrEP if they are so 
determined to. 
 
Finally, I discuss whether the harm caused by PrEP in the absence of effective targeting is great 
enough to justify making the drug unavailable to the entire population. 
 
PIT target population 
 
An overview of common PrEP eligibility has already been provided, though here it is necessary to 
provide greater detail on the PIT’s access criteria. 
 
To access PrEP through the PIT, individuals must be aged 16 years or over and undergo a clinical 
risk assessment at a GUM clinic (PrEP Impact Trial, 2017c). The purpose of assessment is to ensure 
they fit into one of the following three groups: 
 
'a) MSM or trans women who currently test HIV negative, who also tested negative earlier 
in the previous 12 months, and who report unprotected sex in the previous three months 
and consider they are likely to have unprotected sex (excluding oral sex) in the next three 
months. 
b) The HIV negative partner of someone with diagnosed HIV, who is not known to be virally 
supressed and with whom unprotected sex is anticipated. 
 




c) HIV negative people who are clinically assessed and considered to be at similar high risk 
of HIV acquisition as those with a partner with HIV who is not known to be virally 
suppressed. In other words someone who doesn’t fall into the criteria set out in a or b 
but whose situation is assessed to be at a similar level of risk.’ (PrEP Impact Trial, 2017c) 
 
These groups are much the same as those deemed eligible in Scotland (NHS Lothian, 2018), Wales 
(Public Health Wales HIV Expert Group, 2018), and Northern Ireland (Sexual Health NI, 2015). 
They are also similar characteristics to those used in various other PrEP trials and studies57 (Molina 
et al., 2015; Grant et al., 2010; McCormack et al., 2016). My focus is primarily on group A as it 
concerns MSM, the focus of this thesis. This encompasses individuals who fit group B but are also 
MSM. Such individuals all fit within the HRI group previously outlined, whilst those who would be 
classed as LRIs would not fulfil these criteria and MRIs would very rarely (see Chapter V). 
 
Reassessment is carried out at quarterly clinic appointments. These visits are also used to assess 
the effectiveness of PrEP in that individual and will attempt to ascertain adherence and changes 
to risk behaviour. 
 
HIV status is confirmed by a 4th generation venous blood HIV test. Other criteria – i.e. questions 
of the potential user’s condom use and adherence – are not able to be confirmed through any 
medical test. It is through conversation with the potential user that this information is obtained. 
Self-reporting is, therefore, the method of monitoring risk compensation and adherence 
throughout the trial. 
 
57 There are some variations, such as the length of time considered when asking about CAS or whether the 




The problem with self-reporting 
 
The most important information to obtain in the initial clinical assessment, aside from the HIV 
status of the potential user, is the history and likely future of CAS. The only way to assess this is 
through self-reporting, meaning healthcare staff must rely on prospective users being honest. 
This is an unreliable way to assess eligibility for access to a drug which has such potentially harmful 
risks associated with it.58 
 
Self-reporting is a widely used method of information collection when assessing the health status 
of individuals, particularly information on health behaviours (Short et al., 2009). However, despite 
the prevalence of self-reporting, the reliability of this method of data collection is questioned 
(Saltzman et al., 1987). 
 
The key issue contributing to the unreliability of self-reporting is the fact humans can – and do – 
lie to serve their own aims. That can be lying to appear in a more positive light, such as claiming 
full adherence to a drug when you are in fact missing doses,59 or lying to portray what is generally 
considered to be a negative characteristic, such as claiming to have regular CAS in order to access 
PrEP. Both actions are with a view to furthering one’s own interests, or perceived interests; 
appearing in a good light and accessing PrEP respectively. In this discussion it is the latter that I 
am concerned with highlighting, though the former provides a means of doing so. 
 
 
58 Nonadherence (see Chapter IV) and risk compensation (see Chapter V). 
59 This is otherwise known as social desirability bias and is particularly relevant to questions of adherence 




The PIT eligibility criteria for group A specify that to access PrEP the potential user must have had 
CAS60 in the previous three months and be likely to have CAS again in the following three months. 
Prospective users are not expected to recall frequency, but just answer yes or no to having had 
CAS in the previous three months. To lie in response to this question is easy; it is a one-word 
answer rather than requiring the individual to fabricate several untruths coherently in any level 
of depth. It seems reasonable to assume an individual wanting to access PrEP when ineligible may 
say yes to having had CAS in the previous three months. 
 
A systematic review of 31 studies which used a social desirability scale61 found that social 
desirability affected the results of 43% (van de Mortel, 2008). Whilst 45% of these studies were 
not influenced by social desirability responding, the fact that nearly the same number were 
demonstrates the prevalence of social desirability bias. If individuals lie to appear more socially 
desirable when it benefits them, it seems reasonable to believe they would lie to appear less 
socially desirable when it furthers their interests. A more content-relevant study of the validity of 
self-reported condom use in a high-risk population found no association between self-reported 
condom use and fewer incidences of STIs (Zenilman et al., 1995). This suggests reporting bias in 
self-reported condom use.  
 
Another way an individual could dishonestly obtain PrEP during a PIT clinical risk assessment is to 
claim he has an HIV+ partner, thus fulfilling the criteria for group B. This lie could be supported 
by him asking a friend who is HIV+ to pretend to be his partner, which is feasible for many MSM. 
Doing so would lead to that individual being deemed eligible for PrEP. Whilst it is not impossible 
 
60 The criteria specify ‘unprotected sex’, though I am concerned only with MSM so unprotected sex would 
entail CAS. Unprotected oral sex is rarely included in such classifications. 




an individual would attempt to obtain PrEP in this way, it seems very unlikely. If an individual 
ineligible for PrEP wanted to obtain the drug dishonestly, it is far easier to claim to have had CAS 
in the previous three months than to fabricate a more detailed scenario involving a fake HIV+ 
partner. 
 
Flaws in self-reporting are not limited to intentional deception by the individual concerned. 
Human error in the form of forgetfulness and difficulties with recall is also problematic. The 
National Institute on Drug Abuse’s Risk Behaviour Assessment, which seeks to assess an 
individual’s risk of HIV infection, asks questions regarding sexual behaviour and drug use only in 
the previous 30 days (Alcohol and Drug Abuse Institute). This is because longer recall periods 
result in less accurate reporting, so an individual being asked about the previous three months is 
likely to provide less accurate information than if asked about the last month, or even the last 
fortnight. Whilst these issues, and others, are important when considering self-reporting as a 
method overall, they are not particularly relevant in the case of clinical risk assessment for PrEP 
access. Users are asked whether they have engaged in CAS in the previous three months at all 
rather than how many times they have done so, which is far easier to recall; 100% accuracy of 
recall in all cases is still not a realistic expectation, but with a binary question concerning an 
extended time period it is likely to be close to 100%. However, that is close to 100% accuracy of 
recall and does not necessarily mean close to 100% accuracy of response. 
 
There is a final and even more unfortunate problem associated with the use of self-reporting. 
That is the lack of a suitable alternative. For all its flaws, self-reporting is the only method of 
gathering data such as that required in a clinical risk assessment for PrEP. The only way to obtain 
entirely reliable data would be surveillance of prospective users, which is a suggestion that need 




dishonesty are minimal. The potential implications of self-reporting are what spark ethical 




One means of deceitful access to PrEP is so-called “clinic hopping”, or “PEP as PrEP” (PrEP in 
Europe Initiative, 2017). This is a practice whereby those who want to access PrEP for free either 
when PrEP is unavailable or they do not fulfil eligibility criteria do so by presenting at clinics for 
PEP, falsely claiming a risk of exposure to HIV. This is possible because PEP and PrEP use the same 
drug. It also takes advantage of the level of confidentiality upheld at GUM clinics; each clinic is 
independent in terms of patient data, so there is no centralised database. Individuals can visit 
multiple clinics to obtain enough of the drug to use as PrEP without being flagged as consistently 
accessing PEP. Blogger Greg Owen notes that some will visit up to three clinics in a  single day to 
obtain enough pills to last three months (Owen, 2015). 
 
Given the nature of clinic hopping, there are no data available on the frequency of the practice. 
However, it is acknowledged on several PrEP blogs and information sites, suggesting it does 
happen and may be common. The popular site Prepster cites clinic hopping as a potential means 
of accessing PrEP (Prepster), whilst Owen’s blog states the practice happens in London ‘a lot’ 
(Owen, 2015). One individual has even admitted to the practice (Alvarenga, 2017). It is also 
mentioned in a review by Public Health Wales (Public Health Wales, 2017). 
 
There is no feasible way to stop clinic hopping. It could be achieved by either restricting access to 




available to the entire population with no eligibility criteria, which would be very damaging overall 
in terms of harm to individuals (see Chapter IV and Chapter V). Clinic hopping may also be stopped 
by the creation of a centralised database of PEP provision, though this is problematic as the lack 
of anonymity may deter those who legitimately need PEP.62 However, what this discussion of 
clinic hopping has demonstrated is that some people who would be/are looking to access PrEP – 
some of whom would/do not fit the clinic criteria – are willing to lie to access the drug. If willing 
to go to the effort clinic hopping requires, it is reasonable to assume they would have no 
reservations about claiming to have had CAS in the previous three months in order to obtain a 
much larger supply of PrEP.63 
 
Targeting difficulties and ethics 
 
Ethical issues surrounding the difficulty with targeting PrEP access effectively can be separated 
broadly into two considerations: (1) whether it is ethically justified to attempt to deny MRIs and 
LRIs access to PrEP, and (2) whether the inability to limit access only to HRIs in practice presents 
an obstacle to PrEP provision altogether. Both will now be discussed, demonstrating that denying 
MRIs and LRIs access to PrEP can be ethically justified both clinically in terms of risk and ethically 
in terms of nonmaleficence, and that difficulties in ensuring only HRIs access PrEP are ethically 
concerning, but are not so concerning as to suggest PrEP should be entirely inaccessible. 
 
 
62 Even if details of PEP access were kept on a separate database to a patient’s standard NHS record, there 
is a risk individuals would fail to realise this. MSM who are not open about their sexuality may fear being 
‘outed’ or stigmatised if information were to leak. This risk would not exist, but if individuals who need PEP 
think it does then it could prove problematic. 




Attempting to deny MRIs and LRIs access to PrEP is only a minor infringement on their autonomy 
if it is an infringement at all even when they clearly want access to the drug. Some may be 
considered as exercising insufficient autonomy due to a false pursuit of protection and lack of 
knowledge of risks, therein failing to fulfil the criteria of intentionality and understanding. For 
these, the denial of access is an instance of nonmaleficence but does not constitute a denial of 
autonomy; the failure to fulfil the criteria would make the desire for PrEP among this group 
insufficiently autonomous. Others will be sufficiently aware of the potential health implications, 
meaning denial of access would be a significant assault on their autonomy, but this seems likely 
to be the minority.  
 
Clinically speaking, MRIs and LRIs are not considered high-risk users as they do not fall within the 
eligibility criteria detailed earlier in this chapter. Even though they are MSM, their risk of HIV 
infection is low in both the relative and absolute sense. As such, they will derive a negligible 
clinical benefit from the use of PrEP. The extent of the benefit of PrEP to these individuals is a 
heightened sense of protection, whereas the purpose of PrEP is to provide actual heightened 
protection from HIV infection. There is no clinical reason to provide MRIs and LRIs with PrEP based 
on their current sexual practices. 
 
This sort of justification is routinely used in healthcare. Patients are not able to request any drug 
they desire, and PrEP should not be an exception. This is partially to do with safety, but also 
concerns justice in the allocation of healthcare resources; if drugs were available through the NHS 
by request rather than clinical assessment the cost would be unmanageable, preventing some 





There is an argument that greater perceived protection is good for mental wellbeing as it can 
remove the perpetual fear of HIV infection that is verging on unhealthy in some individuals 
(Alcaraz, 2015). However, this does not change the clinical facts. PrEP will reduce the risk of HIV 
infection in MRIs and LRIs, but this is by a statistically insignificant amount and is only the case if 
those users are fully adherent to the drug and do not suffer any risk compensation. The 
psychological wellbeing PrEP may afford MRIs and LRIs can be considered countered by the 
increased risk of STIs and the potential increased risk of HIV, making the harms greater than the 
benefits. 
 
Where an MRI or LRI attempts to access PrEP nonmaleficence can justifiably take priority over 
respect for autonomy. There is a risk of nonadherence and risk compensation proving damaging 
to the health of an MRI or LRI if he were to access PrEP (see Chapter IV and Chapter V). This risk 
of harm is significant enough that to allow access to PrEP would fail to respect the principle of 
nonmaleficence.  
 
Further, this particular instance of overriding autonomy is withholding rather than coercion. 
Denial of autonomy is often thought of in relation to forcing interventions upon those who do not 
consent, but in many instances, such as the denial of access to PrEP, it is instead a refusal to 
provide an intervention deemed unnecessary and potentially harmful. Withholding an 
intervention infringes upon the autonomy of the individual far less than does coercion, making 
the former less ethically problematic in that it denies only autonomy rather than both autonomy 
and bodily integrity (see Chapter III). In this case, the potential harm PrEP can cause MRIs and 
LRIs is enough to justify this withholding the intervention and the resulting minor infringement of 
autonomy. As noted by Lepping and colleagues, there is ‘no a priori reason to focus on any one 




following the course of action which is overall most ethically appropriate. In this case, 
nonmaleficence should be prioritised over autonomy. 
 
I have demonstrated both a clinical and ethical justification for denying MRIs and LRIs access to 
PrEP. This is consistent with the reality of trials, studies, and programmes of PrEP, whereby only 
HRIs are deemed eligible. However, preventing MRIs and LRIs who are determined to access PrEP 
from doing so is almost impossible due to the unreliability of self-reporting as a measure of risk. 
The more pertinent ethical discussion in terms of practical application, then, is whether this 
inability to effectively target PrEP access is problematic enough to justify removing access to PrEP 
altogether. 
 
This discussion again comes down to a question of harm and whether nonmaleficence can 
override autonomy. It also feeds into my wider discussion of economic considerations, though 
this is addressed in Chapter VII. If ineligible individuals can access PrEP by lying in a clinical risk 
assessment, it is possible they could come to harm. MRIs and LRIs affected by nonadherence and 
risk compensation may, depending on the extent the phenomena, find themselves at a greater 
risk of HIV infection than before they started taking PrEP, not to mention the increased risk of 
STIs.  
 
Of course, if they were to simply take PrEP as instructed and change nothing else about their 
sexual risk behaviour then there is no harm to them with which to be concerned. In such a 
scenario, those users would merely be taking a clinically unnecessary drug with no wider impact 
on their life than some minor drug side effects. If this were the case, and the case for all MRIs and 




harm; the only issue would be cost, which is discussed in Chapter VII. However, this is not a 
realistic expectation. The extent to which nonadherence and risk compensation would take place 
is up for debate, but both seem likely to happen to some extent. 
 
The ability of MRIs and LRIs to access PrEP also contributes to prevention optimism (see Chapter 
V). As PrEP becomes more widespread, there may be an increase in individuals who are not on 
PrEP themselves engaging in more CAS as they feel protected by the prevalence of PrEP in the 
community. In addition to the harm caused to those inappropriately accessing PrEP themselves, 
this would harm those affected by prevention optimism. Childress and colleagues write that it is 
justifiable for society to intervene in areas of public health ‘to reduce or prevent the imposition 
of serious risk on others’ (Childress et al., 2002). It is possible, then, if the harm caused to various 
individuals when MRIs and LRIs access PrEP is great enough, to justify removing access to PrEP 
for everyone, including HRIs. 
 
However, this harm is not great enough. At least it does not appear to be from existing evidence 
(see Chapter V). Therefore, denying the entire population access to PrEP is not justified in terms 
of problems with targeting given the current state of knowledge. Further studies are required, 
however, to assess the extent of these harms discussed. If it were to be found that many MRIs 
and LRIs are accessing PrEP through deception, and that this is resulting in enough risk 
compensation and prevention optimism to cause significant harm to the population, it is possible 
a complete end to the provision of PrEP would be justified. Given the proven efficacy of PrEP, to 
deny access requires this high standard of justification; as the drug is already available64 it would 
be problematic to remove access without good reason, so research is needed to confirm the 
 
64 In England PrEP is available through the PIT, but this trial is so large it would not be easy to suddenly 




extent of MRI/LRI access to PrEP and resulting risk compensation and prevention optimism. Until 
then, however, it is an unfortunate and unintended consequence of PrEP provision that some 
individuals who do not fit eligibility criteria will be able to access the drug and this may cause 
some level of harm to them and others. The harm to legitimate users of not being able to access 




If it were possible to ensure only HRIs had access to PrEP, the whole debate over PrEP provision 
would be far simpler. However, MRIs and LRIs will access PrEP under current guidelines and 
practices, and there is no simple remedy to this. 
 
Attempts to deny MRIs and LRIs access to PrEP are justified from both a clinical and ethical 
perspective. This is based on risk-related need; these individuals are simply not at enough risk for 
them to derive more benefit than harm from PrEP. Denying access in this situation is a justified in 
terms of nonmaleficence and is proportionate given the potential harms. 
 
MRIs and LRIs accessing PrEP may cause harm to others as well as themselves as a result of 
prevention optimism. This harm, however, is not great enough to justify removing all access to 
PrEP. It is an unfortunate side effect but is not currently a significant enough issue as to tip the 








































This thesis set out to assess the ethical permissibility of state-funded PrEP for MSM in the UK.65 It 
is a pertinent question given the ongoing PIT and surrounding debate, as well as growing 
international discourse on what role, if any, PrEP ought to have in the fight against HIV. In 
addressing the ethical concerns, I have also shed more light on the cost-effectiveness of PrEP by 
highlighting shortcomings of existing analyses based on misunderstandings of such issues. 
 
In this concluding chapter my aim is not simply to summarise what has come before it, but to tie 
together the individually addressed issues and show what they mean going forward. To this end, 
this chapter revisits the economic questions outlined towards the beginning of this thesis, further 
highlighting the shortcomings of existing economic analyses of PrEP provision. Alongside this call 
for further economic studies, I also present ethically defensible policy suggestions and, most 
importantly, demonstrate the significant need for greater research in all areas addressed 




As noted in Chapter II, the cost-effectiveness of PrEP is a key consideration in commissioning 
decisions; if it proves too costly given the benefits it affords it will not be deemed an appropriate 
use of finite resources by NICE (National Institute for Health and Care Excellence, 2008). Chapter 
II also provided an overview of issues with the ‘go-to’ economic analysis of PrEP in the UK 
(Cambiano et al., 2018). These were: full adherence, quarterly HIV tests by users, and a mean of 
 
65 Whilst my initial focus was on the question of state-funded PrEP, many of the issues addressed might be 




4.5 years spent on PrEP. Given my subsequent exploration of these issues it is appropriate to now 
revisit the economic implications. 
 
Full adherence has been demonstrated to be unrealistic in Chapter IV. In this thesis I focused on 
daily PrEP though have also considered event-based usage at times, both of which have been 
demonstrated to be problematic for users in terms of adherence. Whether this is difficulty 
establishing a routine for daily usage, partially due to side effects (Grant et al., 2010), or a failure 
to anticipate an instance of CAS if a user opts for event-based usage (Molina et al., 2015), I have 
shown that to expect users to be fully adherent to PrEP is unrealistic. This is, however, to be 
acknowledged alongside the fact that for nonadherence to prove problematic to the extent of 
being clinically concerning, it would need to be severe, verging on discontinuation. At least that 
is the case for daily PrEP. For event-based usage nonadherence can be more problematic, hence 
my assertion that only daily usage ought to be presented as an option – this is revisited shortly. 
 
The role of adherence in the question of the cost-effectiveness of PrEP is not all that important 
when considering daily PrEP. It is unlikely to make a huge difference to financial considerations. 
Adherence still ought to be encouraged, but nonadherence alone is unlikely to tip the balance 
with regards to the cost-effectiveness of the drug, or indeed its ethical defensibility. 
 
Next is the expectation of quarterly HIV testing. This ties in with the issue of risk compensation 
explored in Chapter V, as quarterly testing should partially control the increased spread of STIs 
that may arise due to risk compensation. However, given the fact risk compensation can have an 
impact on the spread of STIs beyond the MSM community it is not unrealistic to assume the 




effectiveness of PrEP into question. Whilst quarterly testing is enforceable by making it a 
condition of access, it may be limited in its ability to counter the effects of risk compensation 
should the phenomenon arise. 
 
Finally, the question of time spent on PrEP by the average user. This is likely to be one of the 
biggest factors affecting the cost-effectiveness of PrEP as the drug itself is the main cost. The 4.5 
years suggested by the Cambiano study, in addition to being wholly unexplained, seems to be far 
too short for the reasons outlined. As highlighted in Chapter II, the most likely reason a PrEP user 
would stop taking the drug would be entering a closed, monogamous sexual relationship with a 
partner who is either HIV- or HIV+ but virally suppressed. It seems unlikely this would be the 
reality for the majority of PrEP users after 4.5 years, particularly since it is not uncommon for 
MSM couples to maintain open relationships (Levine et al., 2018). There is insufficient evidence 
to accurately suggest the average length of time a user may spend on PrEP, but it is best 
considered an open-ended need that may continue past 4.5 years. The failure of the Cambiano 
study to perform sensitivity analysis to this effect is problematic, so in addition to the need for 
further research into average time until discontinuation it is also important that further economic 
analysis is carried out with this in mind. 
 
Many issues raised with the Cambiano study, and, by extension, those explored throughout this 
thesis, are not hugely problematic in terms of cost-effectiveness when taken alone. It is when 
they occur contemporaneously, as is at least possible, that costs rise and benefits decline. Take, 
for example, a scenario whereby: PrEP users remain on the drug for an average of 10 years; MRIs 
and LRIs access PrEP and suffer risk compensation, before some struggle with adherence and 
eventually discontinue PrEP without reverting to the use of condoms; those in the MSM 




HIV reaches heterosexual individuals. This may sound an almost dystopian worst-case scenario 
whereby all the possible issues associated with PrEP arise at once, but it is not all that unrealistic. 
If these things happen at once the cost-effectiveness of PrEP is far less clear. It would be difficult 
to account for these eventualities fully in sensitivity analyses, but that does not mean efforts 
should not be made. 
 
It is possible even this worst-case scenario could be softened by developments such as LAI-PrEP 
and new methods of effective targeting. Until these happen, however, it seems realistic that PrEP 
could prove cost-ineffective. Nonetheless, what is vital is a new cost-effectiveness study which 
takes these issues into account as best it can. Only with such a study can the discussion of PrEP 




I asserted early in this thesis that cost-effectiveness is not the sole factor that ought to be 
considered in commissioning decisions. Its importance is understandable in a system of finite 
resources. However, a cost-effective intervention is not necessarily appropriate, just as a cost-
ineffective intervention is not necessarily inappropriate.  
 
Given the shortcomings of the Cambiano study, it seems a definitive answer as to the cost-
effectiveness of PrEP in the UK is not yet available. Based on currently available information I 
suggest it seems unlikely it will be cost-saving to the extent suggested by the Cambiano study, 




discussion, let us assume PrEP is demonstrated to be cost-effective and consider what ought to 
be the next steps based on the ethical debate in this thesis. 
 
To begin with potential users, I have argued only HRIs can ethically be provided with PrEP (as is 
in keeping with official access guidelines). The overall harms that would result from PrEP use for 
MRIs and LRIs are such that it would be ethically unjustifiable to allow. The question of whether 
this insults the autonomy of MRIs and LRIs is an interesting point. The withholding-coercion 
distinction becomes relevant here and denying access is justified on the grounds of 
nonmaleficence – allowing these users access to PrEP would cause more harm than benefit. 
 
This raises the question of effective targeting as explored in Chapter VI. It seems almost 
impossible to prevent those who are not considered eligible from accessing PrEP. Whether 
through falsely reporting their risk in a clinical risk assessment, or clinic hopping, when the drug 
remains available at all it will always be available to those who are willing to lie to access it. Before 
the drug was ever available as PrEP, clinic hopping meant individuals were able to access it for 
such a use. As such, clinic hopping cannot be deemed a legitimate objection to the provision of 
PrEP as it would in fact be an objection to the provision of PEP; clinic hopping would continue if 
PrEP were not available. It is an unfortunate truth that there will always be individuals happy to 
cheat the system for their own benefit (perceived or real), but this cannot justify a blanket 
removal of PrEP access. In terms of policy, PrEP access can justifiably be made available to HRIs. 
Whilst problematic, MRIs and LRIs accessing the drug as a result can be marked an unfortunate 





The next policy consideration is mode of dosing; whether we should allow users to choose 
between daily and event-based PrEP. Based on adherence concerns, I have argued for daily PrEP 
to be the default. Alternative approaches – such as event-based and Ts an Ss – make adherence 
far more difficult for users due to the lack of a simple routine. As the insult to autonomy that is 
limiting dosing options is a lesser harm than the risk posed by nonadherence, putting all PrEP 
users on daily PrEP is a proportionate denial of autonomy. This is common practice in medicine 
whereby drugs are prescribed to be taken a certain way; we are not offered different courses of 
antibiotics to suit our routine but are expected to adhere to the most effective dose/routine 
combination to ensure maximum effectiveness. Of course, there must be clinical discretion to 
permit event-based PrEP. This, however, should be used sparingly and only when necessary, such 
as the example given of the man who very occasionally engages in risky sexual activity at 
bathhouses (see Chapter V). 
 
If daily PrEP is to become the default because it is preferential in terms of adherence, current 
research into LAI-PrEP becomes a serious policy discussion. For the same reason of improved 
adherence, I believe it would be ethically justifiable for LAI-PrEP to become the default means of 
administering the drug if introduced. Not only would LAI-PrEP aid users in adherence – the extent 
of effort required on the part of the user is limited to attending a clinic once every 2-3 months – 
but it would also assist healthcare staff in monitoring users. It will be impossible for a user to 
discontinue PrEP without doctors knowing as failure to attend an appointment for the next dose 
would be flagged, enabling efforts to prevent discontinuation. 
 
By only providing users with daily PrEP – or LAI-PrEP if and when the time comes – we are giving 
an immediate boost to adherence. Whilst nonadherence is not necessarily problematic with PrEP, 




aid this adherence further it is important in initial consultations that users are made aware of 
what side effects to expect, and for clinicians to identify users who may require additional 
support. The potential for SMS services to support adherence has been discussed (Liu et al., 
2018), and it is important this idea is further explored and implemented if appropriate.66 
 
Dealing with risk compensation and prevention optimism is a far more complex issue. Similarly to 
nonadherence, risk compensation might be mitigated by effective consultations. It is important 
users have explained to them the consequences of risk compensation and that they be provided 
with condoms and encouraged to use them. Unfortunately, this will not work for all users; there 
are those who view PrEP as a reason not to use condoms and sufficiently acknowledge the risk, 
and for these individuals nothing can be done. However, it is possible appropriate counselling 
may work for some, so it is important to consider the potential benefits and weigh them against 
cost implications. 
 
When it comes to prevention optimism, counselling has little scope to help. As individuals 
affected by prevention optimism are, by definition, not on PrEP themselves they are not easily 
reached as a group. Some will attend GUM clinics for check-ups, so providing some level of 
counselling to all who attend – as is routine anyway – may mitigate prevention optimism slightly 
but is not getting to the root of the problem. Perhaps the best way to address the issue is to focus 
on effective targeting of PrEP provision as herd immunity may be assumed by fewer individuals if 
there are fewer people on PrEP. This, however, brings us back to the difficulty in effectively 
targeting PrEP at HRIs only. It seems for now prevention optimism must, much like clinic hopping, 
exist as an unfortunate side effect of PrEP provision. There is a clear need to research ways of 
 
66 This would include cost considerations, though it is likely to be a negligible additional cost as SMS services 




effective targeting in order to prevent the issues associated with it, and this should be the focus 
of efforts in this area. 
 
One final policy consideration is the question of privately funded PrEP. Whilst some of the ethical 
issues arise from widespread availability of PrEP, some are just as problematic when only a small 
number of users access the drug. For instance, an MRI or LRI purchasing PrEP online may still 
suffer both nonadherence and risk compensation. The question then arises over whether efforts 
should be made to prevent access to PrEP entirely. There is not space to fully explore this in this 
thesis, though it is an interesting question. There are many points to consider: would permitting 
private purchase but not state provision create a socioeconomic divide in PrEP access?; if PrEP 
were restricted entirely should those who still manage to obtain it receive support from GUM 
clinics?;67 if PrEP restriction were sought, would it be enough to discourage individuals or would 
criminalisation be appropriate? These are interesting and important questions to explore, but it 




All conclusions reached and suggestions made are based on currently available evidence and the 




67 Currently, and prior to the start of the PIT, those who purchased PrEP online were still able to seek 




Firstly, the question of the theoretical positions adopted throughout. There are myriad 
conceptions of each principle and value outlined and applied, meaning some readers will 
inevitably disagree with my usage. In particular, the distinction between coercion and withholding 
does rely on agreement with certain fundamental ideas concerning bodily integrity and a 
somewhat quantitative consideration of values (i.e. only undermining autonomy is preferable to 
undermining both autonomy and bodily integrity).  
 
There is also the issue of limited evidence. As I have highlighted throughout this thesis, my 
arguments are based on currently available evidence. This has, in many cases, been limited. In 
some cases this is simply due to no research having yet been done on the issues I touch on, and 
in others it is owing to the practical and methodological difficulties in obtaining the relevant data. 
For example, evidence of risk compensation among LRIs is limited to personal testimonies as trials 
have sought to recruit primarily HRIs. Some data is also unavailable at present due to its 
longitudinal nature (i.e. how long the average user spends on PrEP). 
 
In a similar vein, any future evidence contrary to the premises central to this thesis may raise valid 
objections to my arguments. For instance, the average PrEP user in the UK may end up being on 
the drug for the 4.5 years suggested by Cambiano and colleagues (Cambiano et al., 2018). If this 
proves to be the case it means the base cost of PrEP will be lower than I have suggested. It may 
also transpire that risk compensation is minimal and users are mostly fully adherent. Whilst I 
consider it unlikely such evidence will arise, it remains a possibility and must be acknowledged.  
 
Finally, there is the limitation of international applicability. I have written this thesis based almost 




but will not be a perfect fit owing to a variety of country-specific factors. Particularly where the 
means of dispensing HIV drugs is concerned; clinic hopping may not be possible, or at least may 
be significantly more difficult, in a country that restricts access to PEP. 
 
These limitations do not immediately question the contribution of this thesis. Most are potential 
limitations as a result of future research. The only limitation that is currently relevant – in terms 
of questioning the contribution of this thesis – is the potential for individuals to disagree with my 
theoretical stances. This is to be expected in the field of bioethics and, therefore, does not 
undermine the value of this thesis to the ongoing debate. Indeed, drawing on Ives’ fallibilistic 
conception of bioethics, the purpose of research in this field is not to find the solution, but a 
solution which ‘goes some way towards resolving the problem we currently have’ (Ives, 2014). 




The key takeaway from this thesis is that we need more evidence and a greater focus on mindful 
deliverance. I am concerned about the implications of the rush to make PrEP available and think 
it important to take a step back and consider how we can best utilise the drug in reducing the 
spread of HIV. 
 
To suggest PrEP is inherently unethical would be a strong and frankly unsupportable claim. 
Rather, I hold that the nature of PrEP provision as it stands is such that many ethical issues arise 
which, in combination, suggest the provision of PrEP as per the PIT model is ethically problematic. 




better informed ethical analysis and commissioning decisions. Only then might PrEP be made 
available in an ethically appropriate manner, with due attention to potential pitfalls. PrEP 
undoubtedly has a role to play in the future of HIV prevention, but the hurried nature of current 
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